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ABSTRACT 
Background Arsenic is a ubiquitous, naturally occurring metalloid that poses a significant risk 
for human cancer and non-cancer diseases. While water consumption provides the majority of 
human exposure to arsenic, millions of individuals worldwide are significantly exposed through 
naturally occurring levels of arsenic in grains, vegetables, meats and fish, as well as through food 
processed with water containing arsenic.  
Objectives This research estimates the global burdens of disease for bladder, lung and skin 
cancers as well as coronary heart disease attributable to inorganic arsenic in food. 
Methods In order to determine foodborne inorganic arsenic exposures worldwide, this research 
uses the World Health Organization’s estimates of food consumption in 13 country clusters, in 
conjunction with the reported measurements of total and inorganic arsenic in different foods. 
This research estimates slope factors for arsenic related bladder and lung cancers, and adopts the 
US Environmental Protection Agency skin cancer slope factor to calculate the annual risk of 
cancer incidence in males and females within each country cluster. Benchmark dose and 
reference dose for arsenic induced coronary heart disease are derived using US Environmental 
Protection Agency Benchmark dose modeling software.   
 v 
Results The research findings show that each year across the world 9,129 to 119,176 additional 
cases of bladder cancer; 11,844 to 121,442 of lung cancer; and 10,729 to 110,015 of skin cancer 
are attributable to inorganic arsenic in food. For coronary heart disease, foodborne inorganic 
arsenic can cause up to 329,750 additional cases annually in USA and even higher rates in 
GEMS clusters with higher foodborne arsenic exposures. However, in contrast to cancer burden, 
there is a threshold effect resulting in no increased risk of heart disease at the expected lower 
bound of arsenic consumption in food. 
Conclusions These estimates indicate that foodborne arsenic exposure causes a significant global 
burden of human disease.  
Public Health Impact Estimating the global burden of disease caused by arsenic exposure in 
food will support policies that reduce exposure to disease promoting environmental hazards. 
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1.0  INTRODUCTION 
1.1 ARSENIC OVERVIEW 
Arsenic is a naturally occurring metalloid that is found in both organic and inorganic forms. It is 
the twentieth most abundant element in the earth’s crust and also gets introduced into the 
environment by anthropogenic activity. In the natural environment arsenic frequently exists in its 
inorganic form as a component of ores and is concentrated on the continental crust of earth at 
approximately 1.5 to 2 parts per million (Arsenic, 1977).  Inorganic arsenic can exist in four 
valence states: -3, 0, +3 and +5, depending upon the environmental conditions. The two most 
common oxidation states are arsenate (e.g., As (V)) and arsenite (e.g., As (III)) that exist in 
oxidizing and mildly reducing conditions respectively (Duker, 2005). Valence states may 
interchange in accordance with the pH and the presence of other substrates (Freeman, 1993).  
Inorganic arsenic often complexes with copper, lead, iron, nickel, cobalt, silver, thallium and 
other metals yielding more than 245 mineral forms of arsenic (Arsenic, 1977). Arsanilic acid, 
methylarsonic acid and dimethylarsinic acid are the most common organic arsenic compounds 
whereas the most common inorganic compounds exist as arsenic trioxide, sodium arsenite, and 
arsenates (e.g., lead arsenate) (WHO, 2000).  
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In sedimentary rocks and soils, arsenic is found in combination with sulfides, hydroxides, 
manganese and iron (Rehman et al., 2012). Generally the soil concentrations of arsenic are 5 to 6 
ppm approximately, but they can vary between 0.2 to 40 ppm across various geographic regions 
(Jones, 2007). In the vicinity of copper smelters, the levels of arsenic in soil have been found 
ranging from 100 to 2500 mg/kg (Diaz-Barriga, 1993).  
Volcanic activity is the primary source of natural airborne arsenic whereas the smelting of 
metals, fuel combustion and pesticide use form its major anthropogenic sources. In the United 
States, the average level of arsenic in ambient air ranges from <1 to 3 ng/m
3
 in remote areas and 
20 to 30 ng/m
3
 in urban areas (ATSDR, 2007). Climate and geology influence the level of 
arsenic in the ground water (Bhattacharya, 2007). Arsenic exists at high levels in sediments of 
rivers and lakes. Various pockets of the US including New England, Maine and areas in the West 
including Arizona, New Mexico, Nevada and Utah have high levels of arsenic (Brown, 2002). 
At the global scale countries like Bangladesh, India, Taiwan, Mexico, China, Argentina and 
Chile have the highest arsenic concentration in the groundwater (ranging to low parts per 
million) in many areas (WHO, 2000). High levels of arsenic and other metals in natural 
groundwater sources pose a major threat to public health worldwide. About 45 million people in 
Bangladesh are exposed to disease-inducing high levels of arsenic in drinking water (more than 
the WHO guideline of 10 μg/L) (Flanagan et al., 2012). Factors like pH, reducing and oxidizing 
conditions composition of the solution and temperature can determine the amount of arsenic that 
gets solubilized into the ground water from the bedrock (Focazio et al., 1999; Nordstrom, 2002). 
Additionally, high levels of groundwater arsenic are directly influenced by specific 
environmental conditions. Closed basins in arid to semi-arid climates and strongly reducing 
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aquifers composed of low sulfate alluvial sediments are typically inducing of higher levels of 
arsenic in ground water. Dissimilatory arsenate-reducing prokaryotes can reduce and/or oxidize 
arsenic containing soils and water - thus enhancing the levels of arsenic in the ground water 
(Focazio et al., 1999).  
1.2 ARSENIC EXPOSURE THROUGH FOOD 
While isolated industrial sources provide significant exposures, the vast majority of individuals 
are chronically exposed to arsenic by ingestion of contaminated food or drinking water.  
According to a recent WHO background document on arsenic in drinking water (WHO, 2011), 
water consumption provides the majority of arsenic exposures and exposure may be more 
harmful due to all of the arsenic in the water being in a toxic form.   
Groundwater is a major source of drinking water in many parts of the world. Concentrations of 
arsenic in groundwater are usually less than 10 μg/L, but they can reach much higher levels in 
some areas (Smedley et al., 2002). Arsenic concentrations are lower in surface waters than 
groundwater. All the arsenic in drinking water is in its inorganic form. Arsenic is present mainly 
as arsenate in oxygenated conditions, such as found in most surface waters. However arsenite 
can be the dominant species in some groundwaters under certain reducing environmental 
conditions. For instance in Bangladesh, the arsenic in ground water is approximately 97% 
arsenite (Postma et al., 2007). 
Naturally occurring levels of arsenic in vegetables, grains, meats and fish, as well as in food 
processed with water containing arsenic (e.g., cooking rice), present significant exposures 
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affecting many millions of individuals worldwide (Yost et al., 1998).  It is unlikely that there are 
individuals who are not exposed to some level of arsenic in food.  However, the extent of human 
exposure to toxic forms of arsenicals in foods is difficult to estimate and highly variable due to 
the natural distribution of arsenic in soils and water (WHO, 2011).  In addition, inert, non-toxic 
organic arsenicals found in seafood and food products made from seaweed can obscure the 
estimates of daily intake of toxic arsenicals. 
1.2.1 Arsenic species in food 
Arsenic levels in food are usually described as total arsenic content, which is the sum of all 
arsenic species. Data on arsenic species is extremely important as different types of foods 
contain different arsenic species with varying toxicities. However, inorganic arsenic is the 
species of greatest health relevance (JECFA, 2011). 
1.2.1.1 Inorganic arsenic species 
Inorganic arsenic species in the environment predominantly include the +3 or +5 oxidation state, 
present as thio- complexes or, primarily as the oxoanions arsenite and arsenate. In food samples, 
inorganic arsenic is often reported as arsenite and arsenate as these are the analytes that are 
actually measured. However the arsenic species are likely non-covalently bound to thiol groups 
in peptides or proteins in the food itself. Since the total arsenic content of food products of 
terrestrial origin is generally low, the overall inorganic arsenic content is low as well with the 
exception of rice. Rice contains significant amounts of inorganic arsenic with concentrations 
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often between 0.1 to 0.4 mg arsenic/kg dry mass or higher (Sun et al., 2008; Meharg et al., 
2009).  
Total arsenic content in fish and other seafood is typically high, i.e., 2 to 60 mg arsenic/kg dry 
mass (SCOOP, 2004; Julshamn et al., 2004) and the levels of inorganic arsenic are <0.2 mg 
arsenic/kg dry mass (Edmonds et al., 2003; Sloth et al., 2005; Sirot et al., 2009). However, edible 
marine alga hijiki (Hizikia fusiforme, also called hiziki) has exceptionally high inorganic arsenic 
concentrations (as arsenate) of >60 mg/kg (FSA, 2004) and blue mussel (Mytilus edulis) can 
have inorganic arsenic concentrations up to 30 mg/kg dry mass (Sloth et al., 2008). 
1.2.1.1 Organic arsenic species 
The major organoarsenic compounds found in foods are arsenobetaine, arsenosugars and 
arsenolipids. More than 50 organoarsenic compounds have been reported in marine organisms 
that are used as food items. Most of these usually occur only at trace levels. Arsenosugars and 
arsenolipids are mainly metabolized in humans to dimethylarsinate, but no specific information 
is available regarding their toxicity. Risk to human health due to arsenosugars, arsenolipids, 
methylarsonate and dimethylarsinate has not been characterized.  
Arsenobetaine is the major form of organic arsenic found in fish and most seafood and is widely 
assumed to be of no toxicological concern (EFSA, 2009). Arsenobetaine occurs in minor levels 
in some mushroom species (Francesconi et al., 2002) and in marine algae (Nischwitz et al., 
2005). Arsenosugars are the dominant arsenic species in algae. Arsenobetaine is also found in 
freshwater organisms at much lower levels than those found in marine samples (<0.1 mg 
arsenic/kg dry mass) (Slejkovec et al., 2004; Schaeffer et al., 2006). Arsenobetaine can be 
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present at higher concentrations in farmed freshwater fish (aquaculture products) because they 
are provided with feed containing marine ingredients (Soeroes et al., 2005).  
Major arsenical constituents of marine algae are arsenosugars (2 to 50 mg arsenic/kg dry mass). 
Arsenosugars are also found at significant concentrations in animals feeding on algae (e.g., 
mussels and oysters; 0.5 to 5 mg/kg dry mass) (Francesconi et al., 2002; EFSA 2009) and at 
lower concentrations in many other marine organisms.  
Arsenolipids are lipids that contain arsenic. The structures of some of these arsenolipids have 
only recently been elucidated although arsenolipids in fish were first reported in the late 1960s. 
Six arsenic-containing fatty acids are found in cod-liver oil (EFSA, 2009; Rumpler et al., 2008). 
Arsenolipid content has been found to vary between about 4 to 12 mg arsenic/kg of oil 
(Schmeisser et al., 2005; Taleshi et al., 2008) in the fish oils examined so far. 
Among other organoarsenic species, methylarsonate, dimethylarsinate, trimethylarsine oxide, 
and tetramethylarsonium ions are often found in organisms generally at low concentrations (<0.5 
mg arsenic/kg dry mass) (Francesconi et al., 2002). Arsenocholine also occurs commonly, but 
generally at modest levels, in marine organisms (typically <0.2 mg arsenic/kg dry mass) (EFSA, 
2009).  
1.3 ARSENIC TOXICOKINETICS 
Inorganic arsenic (As (III) or As (V)) has a complex metabolism and is readily absorbed through 
the gastrointestinal tract (NRC, 2013; WHO, 2000). Human tissues, blood, and urine contain a 
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mixture of arsenic metabolites that vary in acute and chronic toxicity (NRC, 2013). Rate and 
extent of methylation varies between different species as well as among humans (Hughes et al., 
2011). In mammals arsenic is transported to the liver after being absorbed through the 
gastrointestinal tract. Arsenic gets transported and distributed throughout the body through blood 
and is rapidly excreted through urine (Thomas et al., 2001). Human autopsy data indicate that the 
highest absolute amounts of arsenic are found in lungs, kidneys, and skeletal muscle (WHO, 
2000); however, high levels of arsenic accumulate in skin, nails and hair. 
Following low to moderate exposures to arsenic, the absorbed portion of pentavalent arsenic gets 
reduced to its trivalent form (Vahter, 2002). Metabolism of inorganic arsenic (presented in detail 
below) produces various arsenic species that differ in toxicity, rates of elimination and tissue 
distribution (NRC, 2014). The mode of action of inorganic arsenic might be influenced by the 
type of tissue, and exposure factors. The rate of uptake, intracellular distribution and the 
expulsion rate of different arsenic metabolites varies with the tissue type. This in turn leads to 
variation in toxicity of the different metabolites (Dopp et al., 2010). Arsenic methylation 
efficiency varies extensively among tissues with liver having the highest levels of the arsenic (3) 
methyl-transferase enzyme (AS3MT; Kobayashi et al., 2007). Limited human data exists to 
enable physiology-based pharmacokinetic modeling for predicting the concentrations of 
inorganic arsenic in specific tissues (El-Masri et al., 2008). Some evidence exists for the 
formation of arsenical thiols (Fricke et al., 2005). However, as thiols tend to be oxidized upon 
elimination, there is little evidence of its detection in human urine (Raml et al., 2007; Currier et 
al., 2013).  
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Metabolism of arsenic involves sequential steps of reductive and oxidative methylation. The key 
components of arsenic metabolism in this pathway are S-adenosyl methionine (SAM) and 
AS3MT that respectively serve as the methyl donor and the principal enzyme for methylation of 
inorganic arsenic (Hughes et al., 2011; Gamble et al., 2012). Hepatocytes, with the highest 
AS3MT content, take up trivalent arsenic and metabolize it through oxidative methylation to 
methylarsonic acid (MMA(V)) using SAM as a co-substrate. The methylation of MMA(III) by 
AS3MT yields dimethylarsinic acid (DMA(V)), which is considerably less toxic than inorganic 
As (III), As (V), or MMA(III). The ratio of MMA(III) to DMA(V) is most critical in arsenic 
metabolism, because MMA(III) is the most biologically active species. Sulfhydryl groups (-SH) 
on AS3MT may act as the reductant in the absence of GSH (Naranmandura et al., 2006). Most 
species methylate inorganic As species to varying degrees in a process commonly thought to 
involve alternate reduction and oxidative methylation reactions (Hall et al., 2012). Challenger 
proposed the widely accepted classical pathway (Figure 1) for methylation of inorganic arsenic 
(Challenger, 1947 and 1951; Hughes et al., 2011).  
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Figure 1 - Oxidative methylation pathway for inorganic arsenic in mammals 
(Adapted from Hughes et al, 2011 based on Challenger, 1951) 
 
 
 
It has recently been reported that pentavalent arsenic metabolites are hardly metabolized in 
mammals (Rehman et al., 2012). DMA
 
(V) was found to be readily excreted in the urine in an 
unchanged form after oral and parenteral administration in mice and rats. Similarly, in goats, 
sheep, mice and humans, the orally administered MMA(V) was excreted in urine in its 
unmodified form.  These findings suggested that the classical pathway should be reconsidered. 
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Hayakawa proposed an alternative mechanism where a thiol such as glutathione (GSH) or other 
endogenous reductants (like thioredoxin) can catalyze the reduction of arsenic (Hayakawa et al., 
2005). As per this scheme, the oxidation of trivalent methylated metabolites (MMA(III) and 
DMA(III)) produces pentavalent metabolites (MMA(V) and DMA(V)). 
1.4 HEALTH EFFECTS OF ARSENIC  
Inorganic arsenic exposure causes multiple adverse health effects – both cancerous and non-
cancerous - in humans.  The International Agency for Research on Cancer (IARC) has concluded 
that arsenic in drinking water causes skin, bladder and lung cancer; and that there is limited 
evidence of it causing kidney, liver and prostate cancer (Straif et al., 2009). IARC has classified 
arsenic as a Group 1 carcinogen (IARC, 2012).  Heart disease (myocardial infarction), 
respiratory disease, hyperkeratosis, peripheral vascular disease, and possibly hypertension are the 
most common non-cancer causes of mortality and morbidity. Figure 2 depicts the influence 
diagram by which arsenic accumulates in foods and then contributes to adverse human health 
effects. 
Inorganic arsenic and some organic arsenicals consumed have wide ranging pathogenic effects 
that contribute to dose-dependent increased risk for disease.  The exact mode of action (MOA) 
for toxicity from chronic exposures through food or drinking water for the disease endpoints 
shown in Figure 2 remains unresolved.  Hughes et al. (2011) discuss how the most appropriate 
dose response risk assessment model (e.g., linear or non-linear) is still subject to debate and that 
the different disease endpoints, even cancers, may have thresholds for arsenic risk. Figure 2 
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shows that several modes of action may be responsible for adverse arsenic effects; however, the 
modes of action might not be independent and more than one might contribute to different 
diseases. In addition, the pathogenic actions and MOA are dictated by the form of arsenic (e.g., 
valence state, inorganic versus organic, and type of organic arsenical).   
General nutritional status of the exposed individual can also influence the toxic risk, since folate-
dependent one carbon metabolism of inorganic arsenic can both create more toxic methylated 
species and enhance the elimination of ingested arsenic to reduce toxicity (Hall et al., 2012). 
Folate, selenium and vitamin status greatly influence the epigenomic impact of arsenic that is 
increasingly being realized as a major mechanism for disease promotion in adults and imprinting 
for disease risk in-utero.  Nevertheless, foodborne exposure to inorganic arsenic in non-
occupationally exposed adults is undeniably important.  The exposure through rice and other 
food crops that bio-accumulate arsenic, especially in areas with low arsenic levels in water, pose 
a critical risk (Sayarath, 2009). 
1.4 GLOBAL BURDEN OF DISEASE (GBD) DUE TO ARSENIC 
The incidence and/or prevalence of morbidity, disability and mortality associated with acute and 
chronic manifestations of disease can be defined as burden of disease (WHO, 2006). GBD is a 
widely accepted parameter that provides a frame of reference for comprehensive analysis of 
health gaps. It relies on the use of all available mortality and health data by appropriate methods 
to confirm the comparability and consistency of estimates of demographic and epidemiological 
importance worldwide. The World Health Organization has acknowledged the need for an 
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accurate estimation of the extent of foodborne illness to help ensure public health security and to 
enable socioeconomic development worldwide (Kuchenmuller et al., 2009). Scientific evidence 
allows policy makers to prioritize the allocation of limited resources to improve public health in 
the most efficient and effective manner; additionally, it allows informed decisions to be made to 
evaluate the current food safety measures and develop new food safety standards. Knowledge of 
the burden of disease attributable to food toxins helps to assess the cost-effectiveness of 
interventions and to quantify the disease burden in monetary costs. 
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Figure 2 - Foodborne arsenic and disease pathways in humans 
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WHO and other agencies have extensively used the GBD to describe the global, regional and 
national burden from diseases (Murray et al., 1996; Kuchenmuller et al., 2009). Other composite 
measures of population health status such as the disability-adjusted life years (DALY) help to 
define the overall burden of disease. DALY is a time-based measure that “combines years of life 
lost due to premature mortality and years of life lost due to time lived in disability or states of 
less than full health” (Murray et al., 1996). 
This research was conducted as part of the WHO Foodborne Disease Burden Epidemiology 
Reference Group (FERG) efforts to estimate the GBD from foodborne chemical exposures, 
including dietary inorganic arsenic exposure, in response to the increasing global interest in 
health information and addressing a bigger need to fill the current data gap. A partial risk 
assessment was made previously by the Joint FAO/WHO Expert Committee on Food Additives 
(JECFA) who reviewed the provisional tolerable weekly intake (PTWI) of inorganic arsenic with 
an emphasis on the speciation and occurrence of inorganic arsenic in food (JECFA, 2011). 
JECFA (2011) indicated that organic forms of arsenic present in seafood needed different 
consideration from inorganic arsenic and that there have been no reports of ill-effects among 
populations consuming large quantities of fish resulting in relatively high organoarsenic intakes. 
In addition, the human health risks in European countries from foodborne arsenic were assessed 
by the EFSA Panel on Contaminants in the Food Chain (EFSA, 2009).  However, the global 
burden of cancers caused by foodborne arsenic exposure has not been investigated, nor the extent 
of inorganic arsenic content in different diets worldwide. 
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This research focuses on estimating human burden of disease caused by foodborne arsenic 
exposures. The emphasis is on adverse effects associated with inorganic arsenic exposure, 
because it is not clear that foodborne organic arsenic exposure causes human health risk.  
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2.0  METHODS 
Risk assessment can be defined as the process of estimating the magnitude and the probability of 
a harmful effect to individuals or populations from certain agents or activities (Omenn, 2000). It 
involves systematic scientific evaluation of potential adverse health effects resulting from human 
exposures to hazardous agents or situations (NRC, 1983; 1994). Estimation of risk mainly 
involves four steps: hazard identification, dose-response analysis, exposure assessment, and risk 
characterization. 
2.1 HAZARD IDENTIFICATION  
Hazard identification is the process of determining whether exposure to an agent can increase the 
incidence of a particular health condition (Liu et al., 2010). Arsenic exposure is associated with 
an increase in the incidence of bladder, lung and non-melanoma skin cancers in humans. IARC 
has classified arsenic as a Group 1 carcinogen (IARC, 2012). Cardiovascular disease is arguably 
the most important non-cancer disease risk from environmental arsenic exposures, since 
cardiovascular disease is the most common cause of death worldwide and even a modest 
increased relative risk from arsenic exposure translates to very large numbers of excess cases. 
Arsenic exposure at levels present in food is associated with coronary artery disease (CAD), 
myocardial infarctions (MI), and peripheral vascular disease (PVD, a form of ischemic disease). 
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The mortality risk from cardiovascular disease was indeed found to be increased by 22% to 35% 
for arsenic exposure levels of 12 ppb to 148 ppb in a recent prospective study in approximately 
12,000 subjects in Bangladesh (Chen et al., 2011).  
2.2 QUANTITATIVE CANCER RISK ASSESSMENT   
The two key parts of quantitative risk assessment are dose-response (or health effects) analysis 
and exposure assessment. Dose-response analysis involves characterizing the relationship 
between the dose of an agent and incidence of the disease associated with an exposure to this 
agent (Liu et al., 2010). For a toxic agent, exposure assessment includes an estimation of the 
dose i.e. the intensity, frequency, and duration of human exposures. Specifically, this step seeks 
to determine the effects of exposure to toxic agent on the exposed individuals' health (Liu et al., 
2010).  
In this research, the dietary arsenic exposure was multiplied by the cancer potency factor (slope 
factor) for a given cancer endpoint in order to assess the quantitative cancer risk for a given 
population. The global estimate for burden of a particular arsenic-induced cancer was then 
obtained by summing across different populations.  
2.2.1 Dose-response assessment 
Dose response assessment involves quantitative evaluation of the toxicity information in order to 
characterize the relationship between the dose of the contaminant (administered or received) and 
the incidence of adverse health effects in the exposed population. This process is used to derive 
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quantitative toxicity values (i.e., cancer slope factors or reference doses) for comparison to 
environmental exposure levels (US EPA, 2012; Wignall et al., 2014) and can be used to estimate 
the incidence or potential for adverse effects as a function of human exposure to the agent. 
2.2.1.1 Cancer slope factor approach 
Risk of cancer associated with exposure to a carcinogenic or potentially carcinogenic substance 
is estimated by the use of cancer slope factors. A slope factor is an upper bound, approximating a 
95% confidence limit, on the increased cancer risk from a lifetime exposure to an agent by 
ingestion (USEPA IRIS, 1998). It provides an estimate of the probability of a response per unit 
intake of a chemical over a lifetime and is usually expressed in units of proportion of a 
population affected per mg of substance/kg body weight-day.  
This approach is generally reserved for use in the low-dose region of the dose-response 
relationship, i.e., for exposures corresponding to risks less than 1 in 100. The Incremental 
Lifetime Cancer Risk can be estimated by multiplying the cancer slope factor by the chronic 
daily intake. The chronic daily intake represents the dose over a lifetime and is expressed in 
mg/kg-day. 
For the risk assessment considered here, cancer slope factors for bladder cancer and lung cancer 
were derived using data adapted from Morales et al. (2000) where the authors provided a risk 
assessment based on re-analysis of data originally reported in early studies from arsenic-endemic 
region of southwestern Taiwan (Chen et al., 1988, 1992; Wu et al., 1989). The paper by Morales 
et al. (2000) examined model sensitivity and calculated the risk of cancer mortality using 10 
models. Table 8 of this paper (Appendix B) provides the concentration of arsenic in drinking 
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water (g/L) estimated to cause bladder or lung cancer in 1% of males and females in a cohort in 
southwestern Taiwan.  
The derived cancer potency factor was transformed to be relevant to human doses by assuming a 
daily consumption of 2 liters of water per adult in the southwestern Taiwanese population. These 
transformed cancer slope factors were multiplied by arsenic exposures in food for different 
populations worldwide.  For skin cancer caused by inorganic arsenic, the slope factor was 
adapted from the United States EPA IRIS database (US EPA IRIS, 1998). The dietary arsenic 
exposures were collected for all countries of the world using the GEMS cluster diets database 
(WHO GEMS, 2006) to estimate the burden of cancer caused by foodborne arsenic in each 
nation as described in Section 2.2.2.  
2.2.1.2 Reference dose approach for non-cancer disease endpoints 
Reference dose (RfD) is an estimate of a daily exposure to an agent that is assumed to be without 
adverse health impact in humans (Cassarett and Doull’s, 2010). It is the estimated value of the 
daily oral exposure of a population to a toxin that is likely to be without an appreciable risk of 
deleterious effects during a lifetime. Uncertainty associated with RfD can span several orders of 
magnitude. It can be derived from a no observed adverse effect level (NOAEL), lowest observed 
adverse effect level (LOAEL), or benchmark dose (BMD), with uncertainty factors generally 
applied to reflect limitations of the data used and to provide a margin of safety that accounts for 
variability in susceptibility. The RfD is generally used in EPA’s non-cancer health assessments. 
For the estimation of a RfD value for coronary heart disease caused by foodborne arsenic, this 
research relied on the benchmark dose modeling approach. A mathematical model to estimate the 
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lower confidence bounds on a predetermined level of risk (the “benchmark dose” (BMD)) was 
proposed by Crump (1984). BMD is the central estimate of the dose or concentration that 
produces a predetermined change in the response rate of an adverse effect (USEPA: Risk 
Assessment). The predetermined change in response is called the benchmark response (BMR).  
The BMD approach was proposed as a means of avoiding many of the disadvantages of the 
traditional no observed adverse effect level (NOAEL) approach to determine the point of 
departure (POD) from animal toxicology data for use in human health risk 
assessments. However, NOAEL strictly depends on the selected dose, as well as dose spacing 
and the sample size from the study from which the critical effect has been identified. 
Additionally, the NOAEL approach does not consider the shape of the dose-response (Davis et 
al., 2011).  Shallow dose–response, small sample sizes, wide spacing of experimental dosage 
levels, or more than the typical number of dose levels are the major factors that highlight the 
discrepancies between the benchmark dose and the NOAEL. These features tend to make 
determination of the NOAEL more problematic (usually higher) and the confidence limits 
around the maximum likelihood estimate broader (resulting in lower BMDs).  
BMD modeling defines a point of departure (POD) that is largely independent of study design. 
BMD is estimated by fitting of various mathematical models to the observed data. Benchmark 
dose methods involve analyzing each endpoint’s dose response separately. In accordance with 
the EPA’s draft Benchmark Dose Technical Guidance (US EPA, 2012), dose-response modeling 
was conducted using the US EPA’s benchmark dose (BMD) software (BMDS, version 2.4) to 
identify the potential points of departure (PODs) for deriving the RfD by estimating the effective 
dose at a specified level of response (BMDx) and its 95% lower bound (BMDLx). Selecting the 
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BMR(s) involves making judgments about the statistical and biological characteristics of the 
dataset and about the applications for which the resulting BMDs/BMDLs will be used. Typically, 
BMR near the low end of the observable range is selected as the basis for obtaining BMDs and 
BMDLs. These BMD and BMDL values serve as potential PODs to derive quantitative estimates 
below the range of observation and to use for comparisons of effective doses corresponding to a 
common response level across chemicals, studies, or endpoints. 
2.2.1.3 BMD modeling methodology 
BMD analysis can be based on any dose-response study that (i) shows a graded monotonic 
response with dose, and (ii) has the minimum data set for calculating a BMD showing a 
significant dose-related trend in the selected endpoint(s) (USEPA BMDS, 2012). For a better 
estimate of the BMD and a shorter confidence interval, studies with one or more doses near the 
level of the BMR are preferred. 
Studies that do not have a NOAEL (i.e., in which all the dose levels show changes compared 
with control values) are useful for BMD analyses, as long as the lowest response level is not 
much higher than the BMR.  
In any toxicological experiment, various end points or observations can be monitored (USEPA 
BMD, 2012). For the purpose of BMD modeling, endpoint data can be classified into one of 
three categories viz. dichotomous (quantal), continuous and categorical. The clinical signs such 
as mortality due to coronary heart disease can be expressed as a ‘yes’ or ‘no’ response. These 
kinds of data are called dichotomous data. Dichotomous data are quantal data where an effect for 
an individual may be classified by one of two possibilities. 
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Figure 3 - Benchmark Dose Decision tree* 
*(Adapted from USEPA BMD Technical Guidance document, 2012) 
 
 
 
In contrast, the percentage increase in surface area of atherosclerotic lesions is expressed as a 
continuum. Therefore, each animal will have an exact measurement of a value and the group data 
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are usually expressed as mean and standard deviation. These data are called continuous data 
(USEPA BMD, 2012). For each treatment group, the data are expressed as the sample size, mean 
response and standard deviation or standard error. 
For categorical data, the responses in the treatment groups are often characterized in terms of the 
severity of effect (e.g., mild, moderate, or severe histological change).  
Data from two distinct studies (one prospective cohort epidemiological study and another animal 
study) were used to arrive at BMDL values.  
Studies selected for BMD calculation 
Rationale for study selection and endpoint selection 
The most representative epidemiological study for arsenic related coronary heart disease (CHD) 
incidence (Moon et al., 2013) was selected based on the literature search presented in Chapter 3.  
BMD approach begins by identifying a criterion for adverse effect. In most analyses, the 
criterion for adverse effect has been the manifestation of disease in a non-exposed population 
(Jacobson et al., 2002). Epidemiological evidence for an association between arsenic exposure 
and CHD is stronger than any other non-cancer disease (NRC, 2013). Hence CHD incidence was 
considered the best disease endpoint for the purpose of deriving a benchmark dose for arsenic. 
Primary data from a mouse study was also analyzed using the BMD software to compare the 
output to that from the epidemiological data. Atherosclerosis is the primary mechanism in the 
etiology of arsenic-related ischemic heart disease. Arsenic-induced atherogenesis has been 
demonstrated in a genetic mouse model of atherosclerosis after low to moderate exposure to 
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arsenic (NRC, 2013; Lemaire et al., 2011). Earlier animal studies have reported that water 
arsenic exposures accelerate and exacerbate atherosclerosis in the apolipoprotein E-knockout 
(ApoE
–/–
) mouse model for atherogenesis (Srivastava et al., 2007, 2009). In these studies, 
atherogenesis was induced by high level arsenic exposure (50 ppm) alone, without the high fat 
diet normally used to induce atherosclerosis in this model (States et al., 2009). These responses 
were clearly linked to the disease predisposition of the mice that appears to be aggravated by the 
arsenic exposure.  
Primary data from the laboratory of our collaborator Dr. Koren Mann (McGill University, 
Montreal, Canada) was analyzed for use in this research for BMD modeling (Table 2). This is the 
first animal study to examine clinical/ pre-clinical modality directly related to coronary heart 
disease conducted with an exposure range that is directly relevant to human exposures. 
Study Information 
Epidemiological study for BMD modeling: (Moon et al., 2013)  
This recent prospective cohort study derives epidemiological data from the Strong Heart Study 
(SHS). SHS is a study of cardiovascular disease and its risk factors among American Indian men 
and women in three geographic areas: an area near Phoenix, Arizona; the southwestern area of 
Oklahoma; and western and central North and South Dakota (SHS, 2006). Moon et al., (2013) 
was based on arsenic measurements from the urine samples of 3575 men and women aged 45 to 
74 years at baseline between 1989 and 1991 and were actively followed through 2008. 
Comparing the highest and lowest quartiles of arsenic concentrations (>15.7 µg/g vs. <5.8 µg/g 
creatinine), the hazard ratios for cardiovascular disease, coronary heart disease, and stroke 
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incidence after adjustment for socio-demographic factors, smoking, body mass index, and lipid 
levels were 1.32 (CI, 1.09 to 1.59; P for trend=0.002), 1.30 (CI, 1.04 to 1.62; P for trend=0.006) 
and 1.47 (CI, 0.97 to 2.21; P for trend=0.032) respectively (Moon et al., 2013). Data on the total 
number of exposed individuals and total incident cases in each arsenic exposure quartile was 
abstracted from this paper for BMD analysis (Table 1). 
Mouse Data for BMD modeling: (Primary data) 
The detailed methodology for in vivo mouse exposure and characterization of atherosclerotic 
lesions are described in detail in Chapter 5. 
Dose response data for BMD analysis 
Dose response data from Moon et al. (2013) and primary mouse data are presented in the Tables 
1 and 2 below. 
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Table 1 - Coronary heart disease incidence endpoints by urine arsenic concentrations  
(µg/g creatinine)  
 
 
Urinary arsenic level 
(g/g Creatinine) (Median) 
Number of people per 
dose category 
Effect (number of 
cases) 
4.2 896 202 
7.5 893 206 
12.4 892 197 
21.8 894 241 
 
(Data for BMD analysis) 
 
 
 
Choice of BMR 
BMR level of 1% extra risk was used to define BMD for dichotomous data from the 
epidemiology study relating arsenic to coronary heart disease incidence. Traditionally BMR 
levels of 1, 5 and 10% are used for BMD analysis of dichotomous data. The 10% response level 
has customarily been used for comparisons because it is at or near the limit of sensitivity in most 
cancer bioassays and in non-cancer bioassays of comparable size  (USEPA BMD, 2012). For 
epidemiological data, response rates of 10% extra risk would often involve upward extrapolation, 
in which case it is desirable to use lower levels and 1% extra risk is often used as a BMR 
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(USEPA BMDS, 2012). BMR of 1% was selected in this analysis as it would reflect 
predetermined level of the slightest increase in risk of coronary heart disease. 
 
 
 
Table 2 - Percentage of atherosclerotic lesion area relative to total aortic sinus area in mice 
exposed to 0-200 ppb of arsenic in water 
 
 
Dose (ppb) 
As in water 
Number of 
animals exposed 
Mean 
Standard 
Deviation 
0 8 0.46 0.91 
10 5 3.05 1.21 
50 5 4.42 2.69 
100 6 8.25 1.48 
200 8 15.56 4.81 
 
 
 
For continuous data, it is recommended that the BMD (and BMDL) corresponding to a change in 
the mean response equal to one control standard deviation (SD) from the control mean always be 
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presented for comparison purposes (USEPA BMD, 2012). Accordingly, BMR level of one 
control SD was used to derive BMD for continuous data obtained from mice study for surface 
area of atherosclerotic lesions. This value was selected as it serves as a standardized basis for 
comparison, akin to the BMD corresponding to 10% extra risk for dichotomous data. 
Selecting a Family or Families of Models 
Nature of the endpoint measurement (i.e., if it is dichotomous or continuous) and the 
experimental design used to generate the data are critical for the initial selection of a group of 
models to fit to the data. For dichotomous variables, probability density models whose 
predictions lie between 0 and 1 for any possible dose, including 0 (like Logistic, Probit, Weibull, 
Multistage, Log-Logistic) are used.  
In the case of continuous variables linear model, polynomial model and power models are 
typically considered if the BMR is expressed as – (i) a change in the mean response, (possibly as 
a fraction of the control mean), (ii) a fraction of the range of the response (when there is a clear 
maximum response), or (iii) a fraction of the standard deviation of the measurement from 
untreated. The Hill model can also be considered, however, it is used only when the biological 
response being studied is known to be receptor-mediated.  
Additionally, model selection is also influenced by certain constraints on the models or their 
parameter values. The number of parameters that affect the overall shape of the dose-response 
curve generally cannot exceed the number of dose groups. EPA BMDS guidance document 
(EPA BMDS, 2012) suggests modeling multiple endpoints simultaneously. The need to specify a 
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small set of models for BMD computation is prevented by the diversity of possible endpoints and 
shapes of their dose-responses for different agents.  
Computation of BMD and BMDL 
Goodness of fit test statistic 
Selection of a fitted model enables the selection of the model that provides an adequate 
description of the data, especially in the region of the BMR (USEPA BMDS, 2012).  A global 
goodness-of-fit measure, usually a p-value is available in the fitting methods. These measures 
quantify the degree to which the predicted means of the dose-group differ from the actual means, 
relative to the expected means variation. Small p-values reflect a poor fit of the model because 
they represent the unlikelihood of the goodness-of-fit statistic to achieve an extreme value if the 
data were actually sampled from the model. Since p-values are estimated under the assumption 
that the different models are correct, they cannot be compared from one model to another and 
can only identify those models that are consistent with the experimental results (USEPA BMDS, 
2012). 
Use of Akaike’s Information Criterion (AIC) is recommended for comparison of models and 
selection of the model to use for BMD computation. Mathematically, AIC is defined as Equation 
(1): 
AIC= 2p−2L …………………………………………………………………….……Equation (1) 
where L is the log-likelihood at the maximum likelihood estimates (MLEs) and p is the number 
of parameters estimated (Akaike, 1973). All else being equal, lower AIC values are preferred.  
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Although the comparison of models from different families (that use a similar fitting method) by 
AIC values is not exact, they can provide useful guidance in model selection (USEPA BMDS, 
2012).  
Scaled residuals of interest is an indication of agreement between the model and the 
observations in the region of particular interest (i.e., the area where the response of interest (the 
benchmark response (BMR)) is found) (USEPA BMDS, 2012). Mathematically, scaled residuals 
is defined as Equation (2): 







 
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errorsStd
valueExpectedvalueObserved
residualsScaled
_
__
_ ………………………..Equation (2) 
Scaled residuals are residuals that have been standardized by dividing by their standard errors 
(SE), i.e., observed minus predicted response divided by SE. Chapter 5 describes the detailed 
steps of BMD computation. 
2.2.2 Exposure assessment 
Exposure to arsenic via food depends on the concentration of arsenic in individual foods and the 
rate of consumption of these food items. The range of inorganic arsenic content, including a 
range of uncertainty and variability for different food groups that represents content in crops 
worldwide, was adapted from values in the literature (Schoof et al., 1999; JECFA, 2011; USEPA 
IRIS, 1998) to derive the mean portion of inorganic arsenic relative to the total food arsenic.  
Using a common range of arsenic content for food crops grown in different parts of the world 
has the advantages of demonstrating the effect of dietary patterns on arsenic exposure via food, 
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and allowing uniformity in calculations across all nations. The range of bioavailability for the 
inorganic arsenic content of various foods was assumed to be 50% to 100% to take into account 
a factor of uncertainty. Thus for each cluster of countries, a lower and an upper bound value of 
inorganic arsenic content at 50% and 100% bioavailability respectively, was estimated.  
To estimate the total bioavailable inorganic arsenic in the diet worldwide, these exposure 
assessment calculations were then consolidated for each relevant population, across all of the 
different foods consumed in different proportions. The GEMS Food Consumption Cluster Diets 
database (WHO GEMS, 2006) was used to gather information on the dietary patterns (amounts 
of specific foods consumed) in different parts of the world, as it divides the world into 13 
clusters of countries based on dietary similarities. The GEMS database uses data from 
FAOSTAT to divide the countries of the world into 13 clusters on the basis of similarities in 
dietary pattern. In the final step, the populations of individual nations across each of the GEMS 
cluster were summed to estimate the global population.  
2.2.3 Assumptions 
The dose response assessment was based on the following major assumptions:  
(i) The southwestern Taiwanese population that provides the dose-response data (Morales et 
al., 2000) used for estimation of the cancer potency factors are reasonably representative 
of global populations in terms of adverse effects of arsenic. This allowed the same cancer 
potency factor to be applied in other parts of the world;  
(ii) The dose-response curves for arsenic-induced cancers can be linearized and driven 
through (0, 0);  
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(iii) The average human consumption of water per day is 2 liters (Morales et al., 2000);  
(iv) The toxicity of inorganic arsenic exposure in drinking water is equal to that of inorganic 
arsenic exposure in food;  
(v) The slope factors for arsenic-related bladder cancer and lung cancer, would not change 
appreciably as a result of infections or co-exposures in the Taiwanese population from 
which Morales et al. (2000) derived the data.  
The primary assumption in the exposure assessment is that the values reported in literature for 
total foodborne exposure to arsenic and the proportion of inorganic arsenic in different foodstuffs 
(Schoof et al., 1999; JECFA, 2011; USEPA IRIS, 1998) are reasonably accurate.  In addition, it 
is assumed that the rough upper and lower bounds for bioavailability of inorganic arsenic in 
foods is 50-100%. For calculations based on populations within each GEMS cluster, it is 
assumed that (i) roughly an equal number of men and women comprise each GEMS dietary 
cluster of nations; and (ii) that the individuals within each GEMS cluster consume roughly 
comparable amounts of the foodstuffs that are presented in the GEMS database, including across 
age groups and genders.  
2.3 RISK CHARACTERIZATION 
Toxicity values viz, reference doses and slope factors are used in this risk characterization step 
for estimating the likelihood of adverse effects occurring in populations exposed at different 
exposure levels.  Studies based on occupational cohorts or studies in experimental animals 
typically provide data useful in this analysis (NRC, 1983).  
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In order to characterize the risk of bladder, lung and skin cancer due to foodborne arsenic, the 
data from dose–response and exposure assessment were integrated to quantify the burden of 
arsenic related cancers across the world. For each cancer type the respective slope factor was 
multiplied with the estimated range of daily dietary inorganic arsenic exposure and the 
population size of the individual GEMS cluster to obtain an annual gender-specific estimate of 
the additional number of foodborne arsenic related cancers.  
To characterize the risk of coronary heart disease, a reference dose (RfD) was calculated based 
on the estimated benchmark dose lower bound (BMDL) values. Uncertainty factors were used to 
adjust a NOAEL, LOAEL, or benchmark dose in order to derive a RfD (USEPA BMD Technical 
Guidance, 2012). Uncertainty can be defined as “a lack of precise knowledge as to what the truth 
is, whether qualitative or quantitative” (NRC, 1994). Uncertainty differs from variability in that 
it can generally be reduced by further research. Uncertainty factors are applied as needed to 
account for extrapolation of results in experimental animals to humans, inter-individual 
variability including sensitive subgroups, extrapolation from a LOAEL to a NOAEL, 
extrapolation of results from subchronic exposures to chronic exposures, and database 
inadequacies.  
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3.0  LITERATURE REVIEW 
3.1 ARSENIC INDUCED CANCERS 
Epidemiological evidence supporting a causal role for arsenic in cancers was estimated as the 
first step to determine if there was substantial proof for bladder, lung and skin cancer in humans 
caused by arsenic. PubMed was searched for all epidemiology studies on arsenic in drinking 
water and cancer of bladder, lung and skin published from January 1966 through December 
2012. Literature was also collected for studies on arsenic-induced renal cancer, prostate cancer 
and liver cancers. The following search terms were included: arsenic, arsenicals, water, cancer, 
lung, bladder, skin, liver, prostate, renal (kidney) and epidemiology. Studies that assessed the 
relation between arsenic exposure (determined using environmental measure of drinking water, 
biomarkers, or indirect measures (living in arsenic-endemic areas)) and clinical outcomes of 
disease endpoints were identified.  
The exclusion criteria were: (i) Non- human studies (experimental studies); (ii) case reports and 
case series; (iii) no chronic arsenic exposure levels in general population settings (e.g., acute 
arsenic poisoning, use of arsenic trioxide as a chemotherapeutical agent, or lewisite, occupational 
exposure); (iv) studies that assess arsenic exposure through air; and (vi) studies originally 
published in another language besides English.  
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There is a significant amount of research literature from studies conducted in five major regions 
of the world with especially elevated levels of naturally occurring arsenic: southwestern and 
northeastern Taiwan, northern Chile, Cordoba Province in Argentina, Bangladesh, West Bengal 
(India) and other regions in the Ganga plain. These provide the strongest evidence for the 
association of human cancer with arsenic in drinking water (IARC, 2012). 
A recent IARC report on several different Group 1 human carcinogens (IARC, 2012) indicated 
that the general population is primarily exposed to arsenic through the oral intake of 
contaminated food or water. Although inhalation of arsenic constitutes an occupational hazard 
for industrial workers, it is considered to be a minor exposure route for the general population 
(IARC, 2012).  
This dissertation focuses on the epidemiological evidence based on cancer risk associated with 
the ingestion - rather than inhalation - of arsenic. As per IARC (2012), ecological studies are 
adequate to deduce causal inference for carcinogenic effects of arsenic in drinking water, mainly 
due to a large contrast in the exposure of different population subsets. Moreover, high ecological 
estimates of relative risk rule out the possibility of potential confounding with known causal 
factors (IARC, 2012). 
3.1.1 Arsenic-induced bladder cancer 
Multiple ecological, case-control and cohort studies indicate an association between arsenic 
exposure and bladder cancer (IARC, 2012).  Ecological studies in southwestern and northeastern 
Taiwan have observed an increase in mortality from urinary bladder cancer due to exposure to 
arsenic via drinking water (Chen et al., 1985, 1988a; Wu et al., 1989, Chen et al., 1990). Tsai et 
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al. (1999) reported an increase in standardized mortality rate (SMR) values by gender during the 
period 1971 to 1994 as compared to the local and national reference groups. Comparable risks 
for bladder cancer were found by an additional study based in the blackfoot disease endemic 
areas of Taiwan (Chiang et al., 1993) using incidence records. Rivara et al. (1997) and Smith et 
al. (1998) found considerably elevated SMR values for bladder cancer in the periods 1950 to 
1992 and 1989 to 1993 respectively, in the aforementioned high-risk region of Chile. Estimates 
of exposure to arsenic in drinking water were also reported to be associated with elevated SMRs 
in ecological studies in Cordoba province, Argentina (Hopenhayn-Rich et al., 1996, 1998). 
Chen et al. (1986) reported an increasing trend in age-sex- adjusted odds ratios (OR) with an 
increase in the duration of consumption of artesian well-water containing arsenic. This was done 
in a case-control study conducted in the blackfoot disease endemic area (BFDEA) in Taiwan 
using death certificates.After adjusting for smoking and other factors from next-of-kin 
interviews, the highest risks were observed in populations exposed for over 40 years to arsenic 
containing well water, with an OR of 4.1 (P<0.01) in a multivariate analysis. The age-sex-
adjusted OR of developing bladder cancer for those who had used artesian well water for 40 or 
more years was 3.90 (P<0.01) as compared with those who had never used artesian well water 
(Chen et al., 1986).  
Numerous case–control studies that included an analysis of incident bladder cancer in urine 
samples, have observed a higher risk associated with arsenic among persons with higher 
MMA(V):DMA(V) ratios (Chen et al., 2003, 2005a), or alternatively, with a higher percentage 
of MMA(V) (Steinmaus et al., 2006; Pu et al., 2007a; Huang et al., 2008; IARC, 2012). Chen et 
al. (2003) reported a substantially increased risk of bladder cancer, in subjects with low 
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secondary arsenic methylation index, especially when combined with high cumulative arsenic 
exposure levels. Steinmaus et al. (2003) reported significantly elevated odds ratios for bladder 
cancer in smokers with arsenic intakes of >80 μg/day (highest 1-year average), 40 or more years 
prior to diagnosis (OR = 3.67; 95% CI:1.43–9.42), but not for ever and never smokers combined 
(OR = 1.78; 95% CI: 0.89–3.56) or for never smokers (OR = 0.31; 95% CI: 0.06–1.66). Among 
smokers, Karagas et al. (2004) reported an elevated OR for bladder cancer for the uppermost 
category of arsenic in toenails (OR 2.17, 95% CI: 0.92–5.11, for greater than 0.330 μg/g 
compared to less than 0.06 g/g) in New Hampshire, US. These data suggested that ingestion of 
low to moderate arsenic levels may affect bladder cancer incidence and that cigarette smoking 
may act as a co-carcinogen. 
Elevated bladder cancer risk was observed following chronic exposure to arsenic in multiple 
cohort studies in different parts of the world viz. southwestern and northeastern Taiwan (Chen et 
al., 1988b; Chiou et al., 1995, 2001), United Kingdom (Cuzick et al., 1992) and Japan (Tsuda et 
al., 1995). Chiou et al. (2001) reported an OR of 1.96 (95% CI: 0.94-3.61, based on 10 cases) in 
Taiwan.  Morales et al. (2000) found estimated concentrations of arsenic in well water that were 
associated with a 1% increase in the risk of developing bladder cancer in a Taiwanese 
population. Aballay et al. (2012) reported an increased risk of bladder cancer in both sexes 
associated with arsenic exposure, based on age-standardized incidence rates for cancer in 
Argentina.  In the BFDEA of Taiwan, Su et al. (2011) reported a decline in the incidence of 
bladder cancer with a reduction in arsenic intake from water.  
Gibb et al. (2011) suggested that the ability of an epidemiologic study of arsenic exposure to 
detect associations with lung or bladder cancer could be impacted by the number of smokers in 
 38 
the study population. Indeed, an increased risk of bladder cancer was reported only in smokers, 
exposed to relatively low concentrations of arsenic in drinking water in multiple studies (Bates et 
al., 2004; Karagas et al., 2004; Steinmaus et al., 2003; Gibb et al., 2011). Earlier studies in 
Finland and USA (Kurttio et al.,1999; Bates et al., 1995) also present evidence of an interaction 
between smoking and arsenic with respect to bladder cancer. In a meta-analysis of 10 studies, 
Begum et al. (2012) reported a strong correlation of the absolute risk of bladder cancer from 
ingested arsenic with smoking rates.  
In a cohort study in Denmark, Baastrup et al. (2008) found no association between the time-
weighted average/cumulative exposures and lung/bladder cancer in the incidence rate ratios 
(IRRs), adjusted for a variety of different variables. Relative risks were not reported by sex. 
Chen et al. (2010b) reported a significant monotonic increasing risk of urinary cancer (p < 0.001) 
with arsenic concentration in a cohort study in northeastern Taiwan. Compared with those 
consuming <10 μg arsenic/L, the age and sex-adjusted RRs (95% CIs) for arsenic levels 10–49.9, 
50–99.9, 100–299.9, and ≥ 300 μg/L were 1.7 (0.56–5.19), 2.49 (0.73–8.59), 4.18 (1.3–12.8), 
and 7.73 (2.69–22.3), respectively. Urinary cancer RRs (95% CIs) for cumulative arsenic 
exposures 400–1,000, 1,000–5,000, 5,000–10,000, and ≥ 10,000 μg/L-year were 1.16 (0.29–
4.64), 2.44 (0.91–6.5), 3.88 (1.18–12.7), and 7.55 (2.79–20.4), respectively, compared with < 
400 μg/L-year.  
3.1.2 Arsenic-induced lung cancer 
A large body of ecological studies indicates that arsenic exposure is associated with increased 
risk for lung cancer mortality (IARC, 2012). In an ecological study based in the aforementioned 
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high-risk region of Chile, Rivara et al. (1997) found the standard mortality ratio to be increased 
for both sexes when compared to the national rates (men, SMR = 3.8 (95% CI, 3.5-4.1); women, 
SMR = 3.1 (95% CI, 2.7-3.7)).  In a 50-year study of lung cancer mortality, the peak lung cancer 
mortality RRs were 3.61 (95% CI, 3.13- 4.16) for men and 3.26 (95% CI, 2.50- 4.23) for women 
in this region, compared within a low-exposure area in Chile (Marshall et al., 2007). An 
ecological study conducted in Cordoba, Argentina found increasing trends for lung cancer 
mortality with arsenic exposure. The SMR values in the high exposure groups were 1.77 for men 
and 2.16 for women, respectively (Hopenhayn-Rich et al., 1998).  
Smith et al. (2006) compared mortality rates in Antofagasta, Chile in the period 1989-2000 with 
those in the rest of Chile. They found that the SMR values for lung cancer for the birth cohort 
born just before the high-exposure period (1950-1957) and exposed in early childhood was 7.0 
(95% CI, 5.4-8.9; p<0.001). For those born during the high-exposure period (1958-1970) with 
probable exposure in-utero and early childhood, the SMR was 6.1 (95% CI, 3.5-9.9; p<0.001) for 
lung cancer (Smith et al., 2006).  Based upon a meta-analysis, Begum et al. (2012) estimate 
about 4.51 additional lung cancer cases per 100,000 people for a maximum contamination level 
of 10μg/L of arsenic. In a case-control study in northern Chile, Ferreccio et al. (2000) found 
increasing levels of arsenic exposure during the years 1958-1970 to be associated with increased 
lung cancer risks (OR 7.1, 95% CI, 3.14-14.8). 
Cohort studies in southwestern Taiwan observed a positive dose response relationship between 
the exposure to artesian well water and lung cancer.  Morales et al. (2000) found estimated 
concentrations of arsenic in well water that were associated with a 1% increase in the risk of 
developing lung cancer in a Taiwanese population.  The age-adjusted OR of developing lung 
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cancer was 3.39 for those who were exposed to arsenic in artesian well water for 40 or more 
years, as compared to those who had never used artesian well water (Chen et al., 1986). Chiou et 
al. (1995) reported a smoking-adjusted increased risk for lung cancer in relation to increasing 
cumulative exposure to arsenic.  
Chen et al. (2004), Ferreccio et al. (2000) and Mostafa et al. (2008) suggested an interaction 
between smoking and arsenic with respect to lung cancer, as was evident by the significantly 
elevated RRs among smokers compared with nonsmokers, both groups being exposed to arsenic.  
In a cohort study, Chen et al. (2004) described 2,503 residents of southwestern Taiwan and 8,088 
residents of northeastern Taiwan, who consumed arsenic-contaminated water for > 50 years. 
When compared with the referent group of <10 μg/L, the adjusted RRs (95% CIs) for lung 
cancers were 1.09 (0.63–1.91); 2.28 (1.22–4.27); 3.03 (1.62–5.69); and 3.29 (1.60–6.78) for 
average arsenic concentrations of 10–99, 100–299, 300–699, and ≥ 700 μg/L, respectively. The 
trend was statistically significant and strong synergism was reported between arsenic in water 
and cigarette consumption.  For those smoking ≥ 25 pack-years, RRs (95% CIs) for lung cancer 
were 3.8 (1.29–11.2), 5.93 (2.19–16.1), and 11.10 (3.32–37.2) for average arsenic concentrations 
of < 10, 10–699, and ≥ 700 μg/L, respectively. 
In the northeastern Taiwan cohort, Chen et al. (2010a) studied 8,086 residents. The RRs and 95% 
CIs for 100–300 and >300 μg arsenic/L when compared with <10 μg arsenic/L were 1.54 (0.97–
2.46) and 2.25 (1.43–3.55), respectively. Although no apparent increased risk was reported at 
concentrations between 10 and 100 μg/L arsenic, these associations tended to increase with 
longer durations of exposure. A synergistic effect of arsenic exposure and cigarette smoking was 
found for squamous- and small-cell carcinomas, but not for adenocarcinoma.  A drastic drop in 
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the lung cancer incidence of BFDEA was reported by Su et al. (2011) as a positive outcome of 
municipal water supply in Taiwan.  
3.1.3 Arsenic-induced non-melanoma skin cancer 
An extensive body of literature definitively links the ingestion of arsenic to increased incidence 
of skin cancer. Multiple ecological studies based on mortality from skin cancer in Taiwan found 
consistent gradients of increasing risk with average level of arsenic in drinking water, as 
measured on the precinct or township level (Chen et al., 1985, 1988a; Chen et al., 1990; Wu et 
al., 1989; Tsai et al., 1999; IARC, 2012). 
SMR value of 3.2 (95% CI: 2.1–4.8) was observed for skin cancer mortality in one region of 
Chile with high arsenic exposures in drinking water during 1976-92, as compared to a relatively 
unexposed control region in Chile (Rivara et al., 1997). Elevated SMR values were reported in 
both sexes (7.7, 95% CI: 4.7–11.9 among men and 3.2, 95% CI: 1.3–6.6 among women) for the 
years 1989-1993 in a later study in this high-risk region using the national mortality rates as 
reference (Smith et al., 1998).  
An eight-fold difference was observed in the prevalence of skin cancer lesions from the highest 
to the lowest category of arsenic concentration (>600 μg/L and <300 μg/L, respectively) in 
artesian wells in southwestern Taiwan, based on a survey in 37 villages with 40,421 participants 
(Tseng et al., 1968). Chen et al. (1988b) reported an SMR of 28 (95% CI: 11–59) for skin cancer 
deaths in a retrospective cohort study of 789 blackfoot disease patients in Taiwan (based on 
seven observed deaths), using Taiwan regional rates as reference. In another cohort study (654 
participants) in southwestern Taiwan, Hsueh et al., (1995) observed an incidence rate of 14.7 
 42 
cases of skin cancer/1000 person–years. They found that the risks were significantly related to 
the duration of consumption of artesian well-water, average concentration of arsenic, duration of 
living in the area endemic for blackfoot disease and the cumulative arsenic exposure index. 
Hsueh et al. (1995) reported similar findings in a nested case-control study conducted within the 
same cohort.  Additionally, case-control studies in New Hampshire, USA suggested increased 
risk of skin cancer was associated with toenail arsenic, especially among smokers (Karagas et al., 
2001, 2004; Hughes et al., 2011).  In a case–control study, conducted in areas of Hungary, 
Romania, and Slovakia, Leonardi et al. (2012) observed a positive association between BCC and 
exposure to inorganic arsenic through drinking water with concentrations < 100 μg/L. They 
reported an adjusted OR of 1.18 (95% CI: 1.08, 1.28) per 10μg/L increase in average lifetime 
water inorganic arsenic concentration. 
In a prospective study based on individual-level data from Bangladesh, Melkonian et al. (2011) 
observed significant synergistic effects between measures of arsenic exposure, smoking and 
fertilizer use. Relative excess risks for the interactions between smoking status and arsenic 
exposure were 0.12 (95% CI: 0.06, 0.19) for water arsenic and 0.11 (95% CI: 0.05, 0.15) for 
urinary arsenic measures, respectively. These relative risk values support a role for smoking in 
modification of the effect of long-term arsenic exposure on skin lesions that are considered 
precursors to arsenic-related skin cancer. IARC (2012) notes that the histological types of skin 
cancer were not reported in a majority of the studies. Moreover, because of the notably high 
SMR values, it is unlikely that the observed associations are entirely due to confounding factors 
such as access to health care. 
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3.1.4 Other cancers  
Liver Cancer 
Numerous studies from southwestern Taiwan have evaluated the risk of liver cancer due to 
arsenic exposure via drinking water (Chen et al., 1985, 1988a; Wu et al., 1989; Chen et al., 1990; 
Chiang et al., 1993; Tsai et al., 1999; IARC, 2012). Rivara et al. (1997) reported a relative risk of 
1.2 (95% CI: 0.99–1.6) in arsenic-exposed region II compared with region VIII, Chile. Liver 
cancer among children born in region II during 1950- 1957 and those exposed in-utero was 
found to have a RR of 10.6 (95% CI: 2.9–39.3, P < 0.001) as compared to the rates in region V, 
Chile (Liaw et al., 2008). Smith et al. (1998) found that the liver cancer mortality in region II, 
Chile during the period 1989–93 among persons ≥ 30 years of age was not significantly elevated, 
using national rates as reference, with the SMR values for both sexes being 1.1 (95% CI: 0.8–
1.5). However, Hopenhayn-Rich et al. (1998) did not find the SMR values to be related to 
arsenic exposure in Cordoba Province, Argentina. Morales et al. (2000) find increased liver 
cancer risk in more highly arsenic-exposed Taiwanese populations, but did not account for 
confounding factors such as aflatoxin exposure or chronic infection with hepatitis B virus 
(HBV). 
As noted in IARC (2012), “the finding of an association with liver cancer in Taiwan but not in 
South America may reflect a more sensitive population in the former region, due to endemic 
hepatitis B. The elevated risk of those exposed in-utero and as young children may reflect a 
combination of greater biological vulnerability in early life (Waalkes et al., 2007) plus the fact 
that young children consume 5–7 times more water per kilogram body weight per day than 
adults (NRC, 1993).” 
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This dissertation relied on the hazard identification of IARC (2012) that did not find sufficient 
evidence to associate arsenic in drinking water with liver cancer.  Recent studies particularly 
from countries, where exposures to aflatoxins and Hepatitis B as well as the background rate of 
liver cancers is not as high as in Taiwan, further support an association between arsenic exposure 
and liver cancer. Smith et al. (2012) have reported an increased risk of liver cancer following in 
utero and childhood exposure to arsenic in drinking water in Chile.  
Renal Cancer 
A vast body of literature reports the relation between arsenic exposure via drinking water and 
cancers of the bladder and kidney (Chen et al., 1985, 1988a; Wu et al., 1989; Chen et al., 1990; 
Tsai et al., 1999; IARC, 2012). However, as noted by the IARC Working Group (2012), “kidney 
cancers consist of both renal cell carcinoma and transitional cell carcinoma of the renal pelvis, 
the latter often being of the same etiology as bladder cancer.” Because arsenic causes 
transitional cell carcinoma of the bladder the possibility of the risk estimate for total kidney 
cancer to be diluted cannot be denied. 
Prostate Cancer 
A recent NRC report (NRC, 2013) acknowledges modest epidemiologic evidence of an 
association between arsenic and prostate cancer. Arsenic exposure has been linked to prostate 
cancer in ecological studies. The studies conducted in Taiwan reported a significant dose-
response relationship between the level of arsenic in drinking water and the risk for prostate 
cancer mortality using several methodological approaches and comparison populations, direct 
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and indirect standardization of rates (Chen et al., 1985, 1988a; Wu et al., 1989; Chen et al., 1990; 
Tsai et al., 1999; IARC, 2012). 
Arsenic concentrations in well water were found to be associated with malignant neoplasms of 
prostate cancer resulting in an age-adjusted increase in mortality (Chen et al., 1990). Causality of 
arsenic and prostate cancer are also supported by an observed decline in mortality with arsenic 
levels in water (Yang et al., 2008). An SMR of 1.45 supporting a dose–response relationship 
between arsenic in drinking water and prostate cancer was observed in an ecologic analysis of a 
cohort of Mormon residents of Utah (Lewis et al.,1999). Garcia-Esquinas et al (2013) in the 
Strong Heart Study of an American Indian cohort in US states of Arizona, North Dakota and 
South Dakota report an association between baseline urinary arsenic concentrations and 
increased prostate-cancer mortality. 
Nonetheless, contradictory observations have also been made in other epidemiological studies, 
regarding associations between prostate cancer and arsenic. Based on mortality data in two 
regions of Chile with high arsenic levels in water, Rivara et al. (1997) report a risk ratio (RR) of 
0.9. While in a cohort study in Denmark, Baastrup et al. (2008) did not observe any increase in 
prostate cancer mortality.  
3.2 ARSENIC-INDUCED CARDIOVASCULAR DISEASE 
As the first step to determine substantial epidemiological evidence supporting a causal role for 
arsenic in cardiovascular disease, a thorough literature search was conducted. PubMed was 
searched for all epidemiology studies on arsenic in drinking water and cardiovascular disease. 
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Existing evidence between arsenic exposure and cardiovascular disease was summarized in a 
recent revised systematic review and meta-analysis (Moon et al., 2012). This review was 
published as an update to an earlier systematic review (Navas-Acien et al., 2005) associating 
cardiovascular diseases with arsenic exposure. These reviews strengthen the evidence for a 
causal association between high chronic arsenic exposure and clinical cardiovascular endpoints, 
while recognizing a need for additional high quality studies at low to moderate arsenic levels. 
For this research, hazard assessment relied on the literature collected in these two reviews as well 
as a search for studies that came out between June 2012 and July 2013.This period was selected 
to include the studies published after Moon et al. (2012) review that were relevant to this 
research. PubMed was searched for epidemiological studies investigating the relation of arsenic 
with cardiovascular disease with following free text and Medical Subject Headings: arsenic, 
arsenicals, arsenic poisoning, arsenite, arsenate, atherosclerosis, carotid artery diseases, coronary 
artery disease, cardiovascular diseases, myocardial infarction, stroke, cerebrovascular disorders, 
peripheral vascular diseases, peripheral arterial disease, mortality, atherosclerosis, 
arteriosclerosis, blackfoot disease.  
Studies that assess the relation between arsenic exposure (determined using environmental 
measure of drinking water, biomarkers, or indirect measures) and clinical outcomes of disease 
endpoints were identified. The exclusion criteria were the same as those used for the literature 
review of arsenic induced bladder, lung and skin cancers (section 3.1):  
(i) non- human studies;  (ii) case report or case series; (iii) no chronic arsenic exposure levels in 
general population settings (e.g., acute arsenic poisoning, use of arsenic trioxide as a 
chemotherapeutical agent, or lewisite, occupational exposure); (iv) no original research (i.e., 
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reviews, editorials, non-research letters); (v) no clinical cardiovascular outcomes (e.g., 
subclinical atherosclerosis); and (vi) studies originally published in another language besides 
English.  
17 studies met the inclusion criterion. Of these, 6 studies were included in the systematic review 
by Moon et al. (2012) and 10 studies in that by Navas-Acien (2005). Only 1 study published 
after Moon et al. (2012), namely Moon et al. (2013) was included in this review (Tables 3, 4, 5, 
6). 10 studies were conducted in high arsenic exposure areas of Taiwan, Bangladesh and Inner 
Mongolia, and 7 studies were conducted in low to moderate arsenic exposure areas in the US, 
Japan and Spain.  
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Figure 4 - Selection process used in a literature review of studies on the relation between 
arsenic and cardiovascular disease 
 
 
 
All the studies can be broadly categorized into high exposure or low exposure analyses 
depending on the highest mean exposure levels of arsenic detected in the study region. The cut-
off for high exposure studies was kept at more than or equal to 150 μg/L of arsenic. Of the 7 
cohort studies, 4 were prospective cohort (Moon et al., 2013; Chen et al., 2011; Sohel et al., 
2009; Chen et al., 1996) and 3 were retrospective cohort studies (Wade et al., 2009; Lewis et al., 
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1999; Lisabeth et al., 2010). 4 studies were ecological (Medrano et al., 2010; Yoshikawa et al,, 
2008; Engel et al., 1994; Wu et al., 1988). 4 studies were cross-sectional in design (Tseng et al., 
1996, 2003 and 2005; Zierold et al., 2004; Chiou et al., 1997) and 1 was a case control study 
(Chen et al., 1988). 
Studies differed in their assessment of arsenic exposure: while some used environmental 
measures, such as arsenic in drinking water at the region/municipal village level (Chen et al., 
2011; Sohel et al., 2009; Medrano et al., 2010; Engel et al., 1994; Chen et al., 1996; Zierold et 
al., 2004; Wade et al., 2009; Lisabeth et al., 2010; Chen et al., 1988), at the household/individual 
level (Wade et al., 2009; Chiou et al., 1997), or in air (Yoshikawa et al., 2008); other studies 
analyzed exposure by calculating an arsenic exposure index accounting for duration of water 
consumption (Tseng et al., 2003; Lewis et al., 1999; Tseng et al., 1996; Tseng et al., 2005).  
The studies also adopted varied methods of ascertainment of the different CVD outcomes. 
Studies ascertaining cardiovascular disease reported mortality by medical records and verbal 
autopsy (Chen et al., 2011; Sohel et al., 2009; Wade et al., 2009) as well as death certificates 
(Wu et al., 1989; Medrano et al., 2010; Engel et al., 1994) or a combination of these as well as 
hospitalization records (Moon et al., 2013) or relied on national health maps (Yoshikawa et al., 
2008). Studies on coronary heart disease mostly used mortality endpoints (Chen et al., 2011; 
Chen et al., 1996; Wu et al., 1989; Medrano et al., 2010; Lewis et al., 1999; Engel et al., 1994), 
although 2 studies ascertained prevalent cases (Tseng et al., 2003; Zierold et al., 2004) and 1 
study identified mortality, as well as total incident cases (Moon et al., 2013).  In the studies 
reporting prevalence endpoints, coronary heart disease was assessed by self-report (Zierold et al., 
2004) or by electrocardiogram (Tseng et al., 2003). Studies on stroke and peripheral arterial 
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diseases mostly reported mortality, although some focused only on disease prevalence. Stroke 
mortality was reported in high exposure studies (Chen et al., 2011; Wade et al., 2009; Wu et al., 
1989) as well as studies conducted in areas with low to moderate exposure to arsenic (<150μg/L) 
(Moon et al., 2013; Medrano et al., 2010; Yoshikawa et al., 2008; Zierold et al., 2004; Lewis et 
al., 1999; Engel et al., 1994). One study from Japan ascertaining stroke and cardiovascular 
disease was identified to be unique as it described exposure to arsenic in air. This led to it being 
incomparable to the rest of the studies that focus on oral route of arsenic exposure in the general 
population. Moreover it cannot be denied that in this population from Japan, rice could 
potentially be a major source of arsenic exposure instead of air. In one study from United States, 
mortalities from vascular diseases were increased in counties where arsenic levels were > 20 ppb 
relative to those with < 10 ppb (Engel et al., 1994).  
The association with high arsenic exposure and peripheral arterial disease (such as blackfoot 
disease) seems to be limited to populations that have poor nutrition (Tseng et al., 2005), while 
that between arsenic and cardiovascular disease is inconclusive at both low and high exposure 
levels. Of all the cardiovascular diseases associated with arsenic exposure, coronary heart disease 
has a well-established clinical cardiovascular endpoint that has been uniformly reported across 
different studies (Chen et al., 2011; Chen et al., 1996; Wu et al., 1989, Medrano et al., 2010; 
Lewis et al., 1999; Engel et al., 1994; Moon et al., 2013). Since the epidemiological evidence for 
an association between arsenic exposure and CHD is stronger than any other non-cancer disease 
(NRC, 2013), CHD incidence was considered the best disease endpoint for the purpose of 
deriving a benchmark dose for arsenic.
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Table 3 - Studies of arsenic exposure and clinical outcome: Cardiovascular disease 
 
 
Study 
Author & 
Year 
Design Population 
Men 
(%) 
Age 
Range 
(years) 
Arsenic 
Exposure 
Assessmen
t 
Exposur
e 
Categori
es - 
RANGE 
Exposu
re 
Categor
ies - 
UNITS 
Endpoin
t 
Ascertai
n--ment 
Outco
me 
No. of 
Cases/ 
NonCas
es 
RR 
typ
e 
Relati
ve 
Risk 
Low
er 
95% 
CI 
Upp
er 
95% 
CI 
Adjustment 
Factors 
HIGH EXPOSURE AREAS >150 µg/L 
Chen et al 
2011 
Prospective 
Cohort 
Araihazar, 
Bangladesh 
NR 18-75 
Baseline 
urine, 
creatinine-
adjusted 
6.6-
105.9 
µg/g 
creatinin
e 
Verbal 
autopsy, 
medical 
records 
CVD 
mortalit
y 
44 
deaths 
HR 
1 -- -- Age, sex, 
education, BMI, 
smoking status, 
and changes in 
arsenic 
concentration 
between visits 
106.0-
199.0 
48 
deaths 
1.15 0.77 1.72 
199.1-
351.8 
54 
deaths 
1.56 1.03 2.38 
351.9-
1100 
46 
deaths 
1.55 1.01 2.37 
Baseline 
concentrati
on of well 
arsenic 
0.1-12 
µg/L 
43 
deaths 
1 
  Baseline age, 
sex, BMI, 
smoking status, 
educational 
attainment 
(years), and 
changes in 
arsenic 
concentration 
adjusted for 
urinary 
creatinine (μg 
per g of 
creatinine) 
between visits 
12-62.0 
51 
deaths 
1.21 0.8 1.84 
62.1-
148.0 
41 
deaths 
1.24 0.8 1.93 
148.1-
864 
63 
deaths 
1.46 0.96 2.2 
 
Sohel et al 
2009 
Prospective 
Cohort 
Matlab, 
Bangladesh 
49.3 15- 75+ 
water 
sample 
from wells/ 
tubewells 
<10 µg/L 
Verbal 
autopsy 
CVD 
mortalit
y 
129 
deaths 
HR 1 -- -- 
Age, sex, asset 
score, and 
education 
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10 to 49 
153 
deaths 
1.03 0.82 1.29 
50 to 149 
476 
deaths 
1.16 0.96 1.4 
150 to 
299 
388 
deaths 
1.23 1.01 1.51 
300 + 
152 
deaths 
1.37 1.07 1.77 
 
Wade et al 
2009# 
Retrospecti
ve Cohort 
Shahai 
village, 
Inner 
Mongolia, 
China 
50 0 -80+ 
Household, 
shared or 
community 
wells levels 
0-5 
μg/L 
Verbal 
descripti
on by the 
family 
and 
medical 
records 
CVD 
mortalit
y 
36 
deaths 
IRR 
1 -- -- 
Age, sex 
education, 
smoking, 
alcohol use, 
farm work 
5.1-20 
12 
deaths 
0.75 0.37 1.51 
20.1-100 
37 
deaths 
1.28 0.79 2.07 
100.1-
300 
15 
deaths 
1.6 0.87 2.95 
>300 2 deaths 5.08 1.45 
17.8
1 
 
Wu et al 
1989 
Ecological SW Taiwan 52 0 -80+ 
Village 
well water 
<0.30 
mg/L 
Death 
certificat
e 
CVD 
mortalit
y 
683 
deaths 
SM
R 
1 -- -- 
Age 
0.30 - 
0.59 
456 
deaths 
1.232 
1.02
7 
1.47
7 
≥ 0.6 
229 
deaths 
1.494 
1.28
6 
1.73
6 
 
LOW-MODERATE EXPOSURE AREAS <150 μg/L 
Moon et al 
2013 
Prospective 
cohort 
USA  
(3 
American 
Indian 
Communiti
es) 
39.8 45-74 
Baseline 
urine 
arsenic 
levels µg/g 
creatinine 
<5.8 
μg/g 
creatinin
e 
Hospitali
zation 
records, 
death 
records 
and 
clinic 
visits 
CVD 
inciden
ce 
(fatal 
and 
non-
fatal) 
265 fatal 
and non-
fatal 
cases 
HR 1 -- -- 
Sex, education, 
smoking status, 
body mass index 
(kg/m2), and 
low-density 
lipoprotein 
cholesterol level 
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5.8-9.7 297 1.14 0.95 1.35 
9.8-15.7 291 1.05 0.87 1.26 
>15.7 331 1.32 1.05 1.28 
Baseline 
urine 
arsenic 
levels µg/g 
creatinine 
<5.8 
CVD 
mortalit
y 
86 cases 1 
  
5.8-9.7 95 cases 1.12 0.83 1.52 
9.8-15.7 
115 
cases 
1.26 0.92 1.73 
>15.7 
143 
cases 
1.65 1.2 2.27 
 
Medrano et 
al  2010 
Ecological 
Spain (651 
municipaliti
es) 
NR >20 
Municipal 
drinking 
water 
levels 
<1 
μg/L 
Death 
certificat
e 
CVD 
mortalit
y 
146,567 
deaths 
SM
R 
1 -- -- 
Age, sex and 
provincial level 
variables 
including 
(income, 
hospital beds, 
CV risk factors, 
dietary factors 
and water 
characteristics) 
1-10 
41,957 
deaths 
1.02 0.99 1.06 
>10 
11,852 
deaths 
1.03 0.98 1.08 
 
Yoshikawa 
et al  2008 
Ecological Japan (264 
municipaliti
es) 
49* NR 5 year 
average 
municipal 
environme
ntal air 
levels 
<0.77 ng/m3 National 
health 
maps 
CVD 
mortalit
y 
14,247 
deaths 
SM
R 
1 -- -- Age, sex 
 54 
0.77 to 
0.9 
0.977 
0.94
2 
1.01
3 
0.9 to 
1.04 
1 
0.96
3 
1.03
9 
1.04 to 
1.2 
1.014 
0.97
5 
1.05
5 
1.2 to 
1.36 
0.961 
0.90
6 
1.02 
1.36 to 
1.60 
1.005 
0.95
8 
1.05
5 
1.6 to 
1.77 
1.001 
0.96
6 
1.03
8 
1.77 to 
2.2 
1.051 
1.01
6 
1.08
6 
2.2 to 2.7 0.958 
0.91
8 
1 
>=2.7 1.029 
0.99
5 
1.06
4 
 
Engel and 
Smith 1994 
Ecological 
US (30 
counties) 
45.3 
35 to 
>64 
Drinking 
water level 
at county 
level 
5 to 10 
μg/L 
Death 
certificat
e 
CVD 
mortalit
y 
76,190 
deaths 
SM
R 
1 -- -- 
Age, sex 10 to 20 
24,037 
deaths 
0.8 
0.78
8 
0.81
2 
>20 
6,157 
deaths 
0.948 
0.85
5 
1.05
1 
Notes: 
# descriptive information abstracted from Xia 2009 but RR values from Wade 2009 
^ Overall cases  
* calculated from Table 1 of  Yoshikawa et al. (2008) 
NR = Not Reported; OR - Odds Ratio; SMR – Standard Mortality Rate; RR - Relative Risk; HR – Hazard ratio 
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Table 4 - Studies of arsenic exposure and clinical outcome: Coronary heart disease 
 
 
Study 
Author 
& Year 
Design 
Populatio
n 
Me
n 
(%) 
Age 
Rang
e 
(year
s) 
Arsenic 
Exposure 
Assessmen
t 
Exposur
e 
Categor
ies - 
RANGE 
Exposur
e 
Categor
ies - 
UNITS 
Endpoint 
Ascertain
-ment 
Outcome 
No. of 
Cases/ 
NonCases 
RR 
typ
e 
Relati
ve 
Risk 
Low
er 
95% 
CI 
Up
per 
95
% 
CI 
Adjustment 
Factors 
HIGH EXPOSURE AREAS >150 µg/L 
Chen et 
al 2011 
Prospectiv
e Cohort 
Araihazar, 
Banglades
h 
NR 
18-
75 
Baseline 
urine, 
creatinine-
adjusted 
6.6-
105.9 
µg/g 
creatinin
e 
Verbal 
autopsy, 
medical 
records 
CHD 
mortality 
17 deaths 
HR 
1 -- -- 
Age, sex, 
education, 
BMI, smoking 
status, and 
changes in 
arsenic 
concentration 
between visits 
106.0-
199.0 
18 deaths 1.29 0.66 
2.5
1 
199.1-
351.8 
17 deaths 1.47 0.72 
3.0
1 
351.9-
1100 
17 deaths 1.9 0.91 
3.9
8 
Baseline 
concentrati
on of well 
arsenic 
0.1-12 
µg/L 
14 deaths 1 -- -- Baseline age, 
sex, BMI, 
smoking status, 
educational 
attainment 
(years), and 
changes in 
arsenic 
concentration 
adjusted for 
urinary 
creatinine (μg 
per g of 
creatinine) 
between visits 
12-62.0 16 deaths 1.22 0.56 
2.6
5 
62.1-
148.0 
15 deaths 1.49 0.79 
3.1
9 
148.1-
864 
26 deaths 1.94 0.99 
3.8
4 
 
Tseng et 
al 2003 
Cross-
sectional 
SW 
Taiwan 
44 
30 to 
>=60 
CEI from 
village 
drinking 
water level 
0 mg/L-y 
Electrocar
diogram 
CHD 
prevalenc
e 
4 cases/73 
non-cases 
OR 1 -- -- 
Age, sex, 
smoking, BMI, 
lipids, 
hypertension, 
diabetes 
mellitus 
 57 
0.1 to 
14.9 
19 
cases/159 
non-cases 
 
1.6 0.48 
5.3
4 
>=15 
50 
cases/157 
non cases 
 
3.6 1.11 
11.
65 
 
Chen et 
al 1996 
Prospectiv
e Cohort 
SW 
Taiwan 
52 
40 to 
>=70 
CEI from 
community 
drinking 
water 
0 
mg/L-y 
Death 
certificate
s 
CHD 
mortality 
4 
deaths/50
5 non-
cases 
RR 
1 -- -- 
Age, sex, 
smoking, BMI, 
lipids, 
hypertension, 
diabetes 
mellitus 
0.1-9.9 
3 
deaths/34
9 non-
cases 
2.16 0.46 
10.
16 
10.0-
19.9 
5 
deaths/46
5 non-
cases 
3.33 0.83 
13.
45 
>20 
13 
deaths/42
0 non-
cases 
4.9 1.36 
17.
68 
 
Wu et al 
1989 
Ecological 
SW 
Taiwan 
52 
0 to 
>80 
village 
drinking 
water level 
<0.30 ppm 
Death 
certificate
s 
CHD 
mortality 
232 
deaths 
SM
R 
1 -- -- Age, sex 
 58 
0.30 to 
0.59 
178 
deaths 
1.432 1.05 
1.9
53 
>= 0.6 99 deaths 1.854 
1.44
1 
2.3
8 
 
LOW-MODERATE EXPOSURE AREAS <150 µg/L 
Moon et 
al 2013 
Prospectiv
e cohort 
USA (3 
American 
Indian 
Communiti
es) 
39.8 
45-
74 
Baseline 
urine 
arsenic 
levels µg/g 
creatinine 
<5.8 
μg/g 
creatinin
e 
Hospitaliz
ation 
records, 
death 
records 
and clinic 
visits 
CHD 
incidence 
(fatal and 
non-fatal) 
202 fatal 
and non-
fatal cases 
HR 
1 -- -- 
Sex, education, 
smoking status, 
body mass 
index (kg/m2), 
and low-
density 
lipoprotein 
cholesterol 
level 
5.8-9.7 
206 fatal 
and non-
fatal cases 
1.05 0.86 
1.2
8 
9.8-15.7 
197 fatal 
and non-
fatal cases 
0.95 0.77 
1.1
9 
>15.7 
241 fatal 
and non-
fatal cases 
1.3 1.04 
1.6
2 
Baseline 
urine 
arsenic 
levels µg/g 
creatinine 
<5.8 
CHD 
mortality 
68 cases 1 -- -- 
5.8-9.7 67 cases 0.99 0.7 
1.4
1 
9.8-15.7 87 cases 1.18 0.83 
1.6
9 
>15.7 119 cases 1.71 0.19 1.4 
 
 
 
Medrano 
et al 2010 
Ecologic
al 
Spain (651 
municipalit
ies) 
NR >20 
Municipal 
drinking 
water 
levels 
<1 µg/L 
Death 
certificate
s 
CHD 
mortality 
46,182 
deaths 
SM
R 
1 -- -- 
Age, sex and 
provincial level 
variables 
including 
income, 
hospital beds, 
cardiovascular 
risk factors, 
dietary factors 
and water 
characteristics 
 59 
1 to 10 
13,213 
deaths 
1.05 1.01 1.1 
>10 
4,062 
deaths 
1.02 0.96 
1.0
8 
 
Zierold 
et al 
2004 
Cross-
sectional 
USA 
(survey 
participant
s with 
private 
wells) 
NR 
Mean
= 62 
Drinking 
water level 
<2 
µg/L 
Self-
report 
CHD 
prevalenc
e 
128 
cases/1,05
7 non 
cases^ 
OR 
1 -- -- 
Age, sex, 
smoking, BMI 
>2-<10 1.52 1 
2.3
5 
>10 (up 
to 2389) 
1.54 0.9 
2.6
8 
 
Lewis et 
al  1999 
Retrospecti
ve Cohort 
(Analyzed 
as 
Ecological) 
USA 
(Mormons) 
52 >1 
CEI from 
community 
drinking 
water 
14 to 
166 
µg/L 
Death 
certificate
s 
CHD 
mortality 
411 
cases/3,64
7 non-
cases^ 
SM
R 
1 -- -- 
Age, sex 
0.896 
0.71
5 
1.1
22 
0.863 
0.67
6 
1.1
02 
 
Engel 
and 
Smith 
1994 
Ecological 
USA (30 
counties) 
49.9 
0 to 
>=65 
county 
drinking 
water level 
5 to 10 
µg/L 
Death 
certificate
s 
CHD 
mortality 
47,090 
deaths 
SM
R 
1 -- -- 
Age, sex 10 to 20 
13299 
deaths 
0.739 
0.66
6 
0.8
19 
>20 
3442 
deaths 
0.842 0.76 
0.9
34 
Notes: 
^ Overall cases and non-cases; NR - Not Reported; CEI - Cumulative Exposure Index; OR - Odds Ratio; SMR – Standard Mortality Rate; RR - Relative Risk; HR – Hazard ratio 
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Table 5 - Studies of arsenic exposure and clinical outcome: Stroke 
 
 
Study 
Author & 
Year 
Design Population 
Me
n 
(%) 
Age 
Rang
e 
(year
s) 
Arsenic 
Exposure 
Assessment 
Exposur
e 
Categori
es - 
RANGE 
Exposur
e 
Categori
es - 
UNITS 
Endpoint 
Ascertain--
ment 
Outco
me 
No. of 
Cases/ 
NonCases 
RR 
typ
e 
Relat
ive 
Risk 
Low
er 
95% 
CI 
Uppe
r 
95% 
CI 
Adjustment 
Factors 
HIGH EXPOSURE AREAS >150 µg/L 
Chen et al 
2011 
Prospect
ive 
Cohort 
Araihazar, 
Bangladesh 
NR 
18-
75 
Baseline 
urine, 
creatinine-
adjusted 
6.6-
105.9 
µg/g 
creatinin
e 
Verbal 
autopsy, 
medical 
records 
Stroke 
mortali
ty 
20 deaths 
HR 
1 -- -- 
Age, sex, 
education, 
BMI, smoking 
status, and 
changes in 
arsenic 
concentration 
between visits 
106.0-
199.0 
20 deaths 0.96 0.52 1.79 
199.1-
351.8 
27 deaths 1.6 0.88 2.9 
351.9-
1100 
15 deaths 1.03 0.53 2.03 
Baseline 
concentrati
on of well 
arsenic 
0.1-12 
µg/L 
19 deaths 1 -- -- Baseline age 
(years), sex, 
BMI, smoking 
status, 
educational 
attainment 
(years), and 
changes in 
arsenic 
concentration 
adjusted for 
urinary 
creatinine (μg 
per g of 
creatinine) 
between visits 
12-62.0 26 deaths 1.35 0.75 2.43 
62.1-
148.0 
18 deaths 1.2 0.63 2.27 
148.1-
864 
22 deaths 1.07 0.54 2.12 
 
Wade et al 
2009# 
Retrospe
ctive 
Cohort 
Shahai 
village, 
Inner 
Mongolia, 
China 
50 0 to 
80+ 
Household, 
shared or 
community 
wells levels 
0-5 μg/L Verbal 
autopsy, 
review of 
medical 
records 
Stroke 
mortali
ty 
40 deaths IRR ref. -- -- Age, sex 
education, 
smoking, 
alcohol use, 
farm work 
 62 
5.1-20 13 deaths 0.62 0.33 1.18 
20.1-
100 
20 deaths 0.65 0.38 1.12 
100.1-
300 
6 deaths 0.58 0.26 1.29 
>300 1 deaths 1.64 0.31 8.77 
 
 
 
 
 
 
Chiou et 
al 1997 
Cross-
Sectiona
l 
Northeast 
Taiwan 
50 
40 to 
>= 
70 
Household 
drinking 
water 
<0.1 µg/L 
Self report 
and medical 
records 
Stroke 
prevale
nce 
9 
cases/995 
non-cases 
OR 1 -- -- 
Age, sex, 
smoking, 
alcohol, 
hypertension, 
diabetes 
mellitus 
 63 
0.1-50 
65 
cases/337
1 non 
cases 
2.53 1.47 4.35 
50.1-
299.9 
38 cases 
1790 non-
cases 
2.78 1.55 4.97 
≥300 
19 
cases/679 
non-cases 
3.6 1.83 7.11 
 
Wu et al 
1989 
Ecologic
al 
Taiwan 52 
All 
ages 
village 
drinking 
water level 
<0.30 
ppm 
Death 
certificates 
Stroke 
mortali
ty 
243 
deaths 
SM
R 
1 -- -- 
Age, sex 
0.30 to 
0.59 
141 
deaths 
1.05
8 
0.86 
1.30
2 
>= 0.6 74 deaths 
1.28
8 
0.99
3 
1.67
1 
 
LOW-MODERATE EXPOSURE AREAS <150 μg/L 
Moon et al 
2013 
Prospect
ive 
cohort 
USA (3 
American 
Indian 
Communiti
es) 
39.
8 
45-
74 
Baseline 
urine 
arsenic 
levels µg/g 
creatinine 
<5.8 
μg/g 
creatinin
e 
Hospitalizat
ion records, 
death 
records and 
clinic visits 
Stroke 
inciden
ce 
(fatal 
and 
non-
fatal) 
55 fatal 
and non-
fatal cases 
HR 
1 -- -- 
Sex, education, 
smoking status, 
body mass 
index (kg/m2), 
and low-
density 
lipoprotein 
cholesterol 
level 
5.8-9.7 75 1.18 0.82 1.69 
9.8-15.7 62 1.16 0.77 1.72 
>15.7 72 1.47 0.97 2.21 
Baseline 
urine 
arsenic 
levels µg/g 
creatinine 
<5.8 
Stroke 
mortali
ty 
6 cases 1 -- -- 
5.8-9.7 17 cases 1.41 0.54 3.67 
9.8-15.7 13 cases 2.16 0.77 6.09 
>15.7 18 cases 3.03 1.08 8.5 
 
Lisabeth 
et al 2010 
Retrospe
ctive 
Cohort 
US (1 
county in 
Michigan) 
47 >=45 
Average zip 
code 
drinking 
water levels 
(population 
weighted) 
0.3 - 
<4.5 
µg/L 
Hospital 
database 
Stroke 
hospita
lization 
14,033 
admission
s* 
RR 1 -- -- 
Age, sex, 
income, race 
 64 
4.5 -
<7.8 
1.26
4 
0.74
1 
2.15
5 
7.8 - 
<9.4 
2.39
8 
1.67 3.45 
9.4 - 
<19.0 
1.38 
0.71
7 
2.66
7 
19 - 
≤22.3 
2.74
3 
1.67 
4.52
5 
 
Medrano 
et al 2010 
Ecologic
al 
Spain (651 
municipalit
ies) 
NR >20 
Municipal 
drinking 
water levels 
<1 
µg/L 
Death 
certificates 
Stroke 
mortali
ty 
38953 
deaths 
SM
R 
1 -- -- 
Age, sex and 
provincial level 
variables 
including 
income, 
hospital beds, 
cardiovascular 
risk factors, 
dietary factors 
and water 
characteristics 
1 to 10 
11862 
deaths 
1 0.96 1.05 
>10 
3211 
deaths 
1.02 0.95 1.09 
 
Yoshikaw
a et al 
2008 
Ecologic
al 
Japan (264 
municipalit
ies) 
47 NR 5 year 
average 
municipal 
environmen
tal air levels 
<0.77 ng/m3 National 
health maps 
Stroke 
mortali
ty 
13,596 
deaths 
SM
R 
Ref -- -- Age, sex 
 65 
0.77 to 
0.9 
1.00
7 
0.97 
1.04
4 
0.9 to 
1.04 
1.01
4 
0.98 
1.05
5 
1.04 to 
1.2 
1.07 
1.02
8 
1.11
2 
1.2 to 
1.36 
0.98
2 
0.95 1.02 
1.36 to 
1.60 
0.94 
0.90
3 
0.98 
1.6 to 
1.77 
0.97 0.94 1.01 
1.77 to 
2.2 
0.95 0.92 0.98 
2.2 to 
2.7 
0.95 0.92 0.99 
>=2.7 
1.01
5 
0.98 1.05 
 
Zierold et 
al 2004 
Cross-
sectional 
USA 
(survey 
participants 
with 
private 
wells) 
NR 
Mea
n= 
62 
Drinking 
water level 
<2 
µg/L Self-report 
Stroke 
prevale
nce 
31 cases/ 
1154 non-
cases^ 
OR 
1 -- -- 
Age, sex, 
smoking, BMI 
>2-<10 0.93 0.4 2.14 
>10 (up 
to 2389) 
1.53 0.6 4.07 
 
Lewis et al 
1999 
Retrospe
ctive 
Cohort 
(Analyze
d as 
Ecologic
al) 
USA 
(Mormons) 
52 >1 Cumulative 
exposure 
index from 
Community 
drinking 
water 
14 to 
166 
µg/L Death 
certificates 
Stroke 
mortali
ty 
176 cases/ 
3882 non-
cases^ 
SM
R 
1 -- -- Age, sex 
 66 
0.79
2 
0.42
4 
1.48
2 
0.68
5 
0.47
4 
0.99 
 
Engel and 
Smith 
1994 
Ecologic
al 
USA (30 
counties) 
49.
9 
0 to 
>=65 
county 
drinking 
water level 
5 to 10 
µg/L 
Death 
certificates 
Stroke 
mortali
ty 
15,166 
deaths 
SM
R 
1 -- -- 
Age, sex 10 to 20 
4,628 
deaths 
0.78 0.69 0.87 
>20 
1,169 
deaths 
0.91 0.74 1.1 
Notes: 
# descriptive information abstracted from Xia 2009 but RR values from Wade 2009; OR - Odds Ratio; SMR – Standard Mortality Rate; RR - Relative Risk; HR – Hazard ratio 
^ Overall cases and non-cases 
* Overall admissions for all exposure categories 
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Table 6 - Studies of arsenic exposure and clinical outcome: Peripheral Arterial disease 
 
 
Study 
Autho
r & 
Year 
Design 
Populatio
n 
Me
n 
(%) 
Age 
Rang
e 
(years
) 
Arsenic 
Exposure 
Assessmen
t 
Exposure 
Categori
es - 
RANGE 
Exposure 
Categori
es - 
UNITS 
Endpoint 
Ascertain--
ment 
Outco
me 
No. of 
Cases/ 
NonCase
s 
RR 
type 
Relat
ive 
Risk 
Lower 
95% 
CI 
Uppe
r 
95% 
CI 
Adjustment 
Factors 
HIGH EXPOSURE AREAS >150μg/L 
Tseng 
et al 
2005 
Cross-
sectional 
SW 
Taiwan 
46 ≥ 30 
total As in 
urine; CEI 
in well 
water 
≤64.33 
or 
>64.33 μg/L and 
mg/L-y 
Ankle 
brachial 
index 
PAD 
preval
ence 
54 
cases/42
5 non-
cases* 
OR 
1 -- -- Age, sex, BMI, 
cholesterol, 
alcohol 
consumption 
≤64.33 3.34 0.6 12.8 
>64.33 3.84 0.86 
17.2
5 
 
Tseng 
et al 
1996 
Cross-
sectional 
Taiwan 45 
53 
(mean
) 
Cumulative 
exposure 
index from 
village well 
water 
0 
mg/L-
years 
Ankle-
brachial 
index 
PAD 
preval
ence 
69 
cases/51
3 non-
cases* 
OR 
1 -- -- Age, sex, 
smoking, BMI, 
lipids, 
hypertension, 
diabetes 
mellitus 
0.1 to 
19.9 
2.77 0.84 9.14 
>20 4.28 1.26 
14.5
4 
 
Wu et 
al 
1989 
Ecological 
SW 
Taiwan 
35 
All 
ages 
village 
drinking 
water level 
<0.30 
0.30 to 
0.59 
≥0.6 
mg/L 
Death 
certificates 
PAD 
mortali
ty 
42 
deaths 
SMR 
1 -- -- 
Age, sex 
58 
deaths 
2.60
1 
1.75 3.87 
22 
deaths 
2.36
3 
1.4 3.98 
 
Chen 
et al 
1988 
Case 
control 
Taiwan 49 <50 - 
≥60 
Years of 
well water 
consumptio
n 
0 years Clinical 
examination 
BFD 
preval
ence 
241 
cases/75
9 non-
cases* 
OR 1 -- -- Age, sex, diet, 
family history 
of BFD 
 69 
1 to 29 3.04 1.58 5.86 
≥30 3.47 1.66 7.23 
 
LOW-MODERATE EXPOSURE AREAS <150 μg/L 
Lewis 
et al 
1999 
Retrospecti
ve Cohort 
(Analyzed 
as 
Ecological) 
USA 
(Mormon
s) 
52 >1 
Cumulative 
exposure 
index from 
Communit
y drinking 
water 
14 to 166 µg/L 
Death 
certificates 
PAD 
mortali
ty 
47 
cases/40
11 non-
cases 
SMR 
1 -- -- 
Age, sex 
0.84
2 
0.437 
1.62
4 
0.60
9 
0.283 
1.31
1 
 
Engel 
and 
Smith 
1994 
Ecological 
USA (30 
counties) 
43 
0 - 
≥65 
County 
drinking 
water level 
5 to 10 
µg/L 
Death 
certificates 
PAD 
mortali
ty 
4,823 
deaths 
SMR 
1 -- -- 
Age, sex 10 to 20 
1,759 
deaths 
1 0.947 
1.05
6 
>20 
621 
deaths 
1.58 1.34 1.88 
Notes: 
*Overall cases and non-cases 
CEI - Cumulative Exposure Index; OR - Odds Ratio 
PAD - Peripheral arterial disease; SMR – Standard Mortality Rate 
BFD - Blackfoot disease; RR - Relative Risk 
BMI - Body Mass Index; HR – Hazard ratio 
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4.0  GLOBAL BURDEN OF DISEASE FOR SKIN, LUNG AND BLADDER CANCER 
CAUSED BY ARSENIC IN FOOD 
4.1 ABSTRACT 
Arsenic is a naturally occurring metalloid that poses a significant human cancer risk. While 
water consumption provides the majority of human exposure, millions of individuals worldwide 
are significantly exposed to arsenic through naturally occurring levels of arsenic in grains, 
vegetables, meat and fish, as well as through food processed with water containing arsenic. This 
dissertation estimated the global burdens of disease for bladder, lung and skin cancers 
attributable to inorganic arsenic in food. To determine foodborne inorganic arsenic exposures 
worldwide, this research used World Health Organization estimates of food consumption in 13 
country clusters, in conjunction with reported measurements of total and inorganic arsenic in 
different foods. The author estimated slope factors for arsenic-related bladder and lung cancers 
and used the US Environmental Protection Agency skin cancer slope factor, to calculate the 
annual risk of the cancer incidence in males and females within each country cluster. The 
research estimated that each year 9,129 to 119,176 additional cases of bladder cancer, 11,844 to 
121,442 cases of lung cancer and 10,729 to 110,015 cases of skin cancer worldwide are 
attributable to inorganic arsenic in food. These estimates indicate that foodborne arsenic 
exposure causes a significant global burden of human disease.  
 71 
4.2 INTRODUCTION 
Arsenic is an environmental toxicant naturally found in drinking water and certain foods. The 
International Agency for Research on Cancer (IARC) classifies arsenic as a Group 1 carcinogen 
based on evidence that inorganic arsenic causes bladder, lung and non-melanoma skin cancer in 
humans (IARC, 2012). Arsenic exposure increases risk of mortality from cardiovascular (Chen et 
al., 2011; Moon et al., 2012) and respiratory diseases (Parvez et al., 2010; von Ehrenstein et al., 
2005).  
Naturally-occurring levels of arsenic in vegetables, grains, meats and fish present a significant 
source of arsenic exposure worldwide (Schoof et al., 1999; Kile et al., 2007; Davis et al., 2012). 
The arsenic comes from uptake by food crops from the soil and irrigation water (Schoof et al., 
1999; Samal et al., 2011; Dittmar et al., 2010; Biswas et al., 2012; Muñoz et al., 2001). Arsenic 
in water can contaminate food during processing and cooking (e.g., in boiling rice, making 
breads or pasta) (Kile et al., 2007; Signes et al., 2008). According to a recent World Health 
Organization (WHO) background document on global arsenic exposure (WHO, 2011), arsenic in 
contaminated water is completely bioavailable and provides the majority of daily arsenic dose 
(Abernathy et al., 2003). However, as arsenic concentrations in water decrease, the relative 
contribution of dietary sources becomes more significant to human arsenic exposures (Kile et al., 
2007; Davis et al., 2012; EFSA, 2009).     
As indicated by its IARC classification, arsenic exposure increases the risk for a number of 
important cancers. Numerous epidemiological studies indicate an association between arsenic 
exposure and an increased risk for lung cancer mortality (IARC, 2012; Gibb et al., 2011; Smith 
et al., 1998; Smith et al, 2009; Ferreccio et al., 2013) and lung cancer may be the leading cause 
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of arsenic-associated cancer deaths. Meta-analysis of available epidemiological studies 
performed in Bangladesh, Chile, Argentina, Taiwan and the United States (Begum et al., 2012), 
estimated about 4.51 additional lung cancer cases per 100,000 people for a maximum level of 
10μg/L of arsenic in drinking water found in the studies. An association between arsenic 
exposure and bladder cancer has been substantiated by multiple ecological, as well as case-
control and cohort studies (see IARC, 2012; Gibb et al., 2011; Smith et al., 1998; Christoforidou 
et al., 2013 for details). An extensive body of literature definitively links the ingestion of arsenic 
to increased incidence of non-melanoma skin cancer, i.e., basal cell and squamous cell 
carcinoma (IARC, 2012). Multiple ecological studies based on mortality from skin cancer in 
Chile, Taiwan, and Bangladesh found consistent gradients of increasing risk with average level 
of arsenic in drinking water (IARC, 2012; Hughes et al., 2011). Cohort studies from IARC 
(2012) reported risks of skin cancer to be significantly related to average concentration of arsenic 
in drinking water and index for cumulative exposure to arsenic (Hughes et al., 2011; Wu et al., 
1989; Hsueh et al. 1995).  
The objective of the study being presented was to use quantitative risk assessment to estimate the 
global burden of foodborne arsenic-induced bladder cancer, lung cancer and skin cancers. Global 
burden of disease (GBD) is a widely accepted parameter that provides a frame of reference for 
comprehensive analysis of health gaps. It relies on the use of all available mortality and health 
data by appropriate methods to confirm the comparability and consistency of estimates of 
demographic and epidemiological importance worldwide. This risk estimate was made as part of 
the WHO Foodborne Disease Burden Epidemiology Reference Group (FERG) efforts to estimate 
the GBD from foodborne chemical exposures, including dietary inorganic arsenic exposure. A 
partial risk assessment was made previously by the Joint FAO/WHO Expert Committee on Food 
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Additives (JECFA) who reviewed the PTWI of inorganic arsenic with an emphasis on the 
speciation and occurrence of inorganic arsenic in food (JECFA, 2011). In addition, the human 
health risks from foodborne arsenic in European countries were assessed by the EFSA Panel on 
Contaminants in the Food Chain (EFSA, 2009). However, the global burden of cancers caused 
by foodborne arsenic exposure has not been investigated, nor the extent of inorganic arsenic 
content in different diets worldwide. 
This study focused on adverse effects associated with inorganic arsenic exposure, since 
foodborne organic arsenical exposures pose little human health risk (Kile et al. 2007; Davis et 
al., 2012; Hughes et al., 2011; JECFA, 2011; EFSA 2009). The author estimated the number of 
additional cases of cancers per year due to inorganic arsenic through food in different diets 
worldwide, based on data adapted from WHO Global Environment Monitoring System 
(GEMS)/Food Consumption Cluster Diets database (WHO GEMS, 2006). GEMS/Food 
Consumption Cluster Diets database divides the countries of the world into 13 groups based on 
diets.  
4.3 RESULTS 
The essential steps of risk assessment are hazard identification, dose-response relationship, 
exposure assessment and risk characterization. The present work relied on hazard identification 
by IARC (IARC, 2012) that clearly identifies arsenic as a human carcinogen with increased risk 
for bladder, lung and non-melanoma skin cancers. The dose response estimates were converted 
for water exposure to human dose to establish the dose-response relationship. Table 7 includes 
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the imputed slope factors for each of the cancers. For bladder and lung cancers gender-specific 
slope factors are reported based on the data adapted from Morales et al. (2000). For skin cancer, 
the slope factors are the same for both genders (USEPA IRIS, 1998). The total increased risk in 
the population of each cancer for every incremental unit of foodborne arsenic was estimated on 
the basis of the slope factors.  
 
 
 
Table 7 - Slope factors, or cancer potency factors, for incidence of each arsenic-related 
cancer 
 
 
Cancer type 
Slope factor (increased 
population risk per µg inorganic 
arsenic/day) 
 Males Females 
Bladder* 0.0000127 0.0000198 
Lung* 0.0000137 0.0000194 
Skin^ 0.000015 0.000015 
 
* slope factor derived by using data adapted from Morales et al. (2000) 
^ slope factor was adapted from the United States EPA IRIS Database (2001) 
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For exposure estimation, Table 8 provides the mean adjusted total arsenic content of foods used 
in the EFSA (2009) dietary exposure estimates along with the conversion factors from total 
arsenic to inorganic arsenic in each of the different foodstuffs provided in JECFA (2011). In 
contrast to water exposures, not all of the arsenic in food is bioavailable and Table 9 presents the 
estimated levels of bioavailable inorganic arsenic for the 13 GEMS food consumption clusters as 
well as the population size for each cluster. For each of these clusters, the GEMS food 
consumption database provides an estimate of the amount of cereals, vegetables, fruits, 
beverages, meat, nuts and oilseeds consumed. Rice and rice products appear to be a major source 
of exposure to inorganic arsenic, especially in GEMS cluster G, comprised of Asian countries.  
Risk characterization of the total estimated cases of bladder, lung and skin cancers attributable to 
foodborne arsenic annually worldwide was calculated from the slope factors in Table 7 and the 
exposure data in Tables 8 and 9. These estimates are listed in Table 10 and can be further 
resolved by GEMS cluster and gender to yield the number of expected additional cases of 
bladder, lung and skin cancer from foodborne inorganic arsenic exposures per year. Table 11 
presents these cases with the assumption of 70 years life span per individual. Overall, the data 
indicate that arsenic in food causes a small but significant burden of the three major cancers that 
is distributed throughout the world. 
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Table 8 - Mean adjusted total arsenic content of foods and the reported conversion factors 
from total arsenic to inorganic arsenic used in the dietary exposure estimates. 
 
 
Food group 
Total arsenic 
lower bound 
mean level (mg/kg) 
Total arsenic 
upper bound 
mean level (mg/kg) 
Mean % inorganic 
Arsenic 
01. All cereal & cereal products 0.0671 0.0848 
30–100^ 01.A Cereal-based dishes 0.0157 0.0283 
01.B Cereal & cereal products 0.0825 0.1017 
02. Sugar products and chocolate 0.0135 0.0320 30-100^ 
03. Fats (vegetable and animal) 0.0063 0.0245 30-100^ 
04. All vegetables, nuts, pulses 0.0121 0.0212 
30-100^ 04.A Vegetable soups 0.0050 0.0110 
04.B Vegetables, nuts, pulses 0.0122 0.0213 
05. Starchy roots and tubers 0.0031 0.0142 30-100^ 
06. Fruits 0.0051 0.0155 30-100^ 
07. Juices, soft drinks and bottled 
water 
0.0030 0.0068 
30-100^ 07.A Fruit and vegetable juices 0.0048 0.0129 
07.B Soft drinks 0.0044 0.0132 
07.C Bottled water 0.0023 0.0041 
08. Coffee, tea, cocoa 0.0034 0.0051 30-100^ 
09. Alcoholic beverages 0.0055 0.0151 30-100^ 
[this category not 
detailed in GEMS diets 
09.A Beer and substitutes 0.0054 0.0161 
09.B Wine and substitutes 0.0061 0.0110 
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^ Data adapted from EFSA (2009) and FAO/WHO JECFA Monographs 8, 2011 
* Reference: Yost et al. (1998) 
 
  
09.C Other alcoholic beverages 0.0085 0.0155 
database and hence was 
not used for 
calculations] 
10. All meat and meat 
products, offal 
0.0044 
 
0.0138 
100* 10.A Meat and meat products 0.0042 0.0137 
10.B Edible offal and offal products 0.0044 0.0139 
10.C Meat-based preparations 0.0121 0.0185 
11. All fish and seafood 1.6136 1.6159 
Standard ratio 
0.015 – 0.10 mg/kg^ 
11.A Seafood and seafood products 5.5537 5.5545 
11.B Fish and fish products 1.4426 1.4549 
11.C Fish-based preparations 1.1524 1.1573 
12. Eggs 0.0042 0.0117 41* 
13. Milk and milk-based products 0.0044 0.0139 
26* 
13.A Milk and dairy-based drinks 0.0026 0.0104 
13.B Dairy-based products 0.0068 0.0184 
13.C Cheese 0.0065 0.0188 
14. Miscellaneous/special dietary 
products 
0.3993 0.4187 
30-100^ 
 
Category not detailed in 
GEMS 
14.A Miscellaneous products 0.2449 0.2658 
14.B Foods for special dietary uses 0.4383 0.4573 
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Table 9 - Range of foodborne total and inorganic arsenic exposure at 50 -100% 
bioavailability for 13 WHO - GEMS clusters of countries
¥
 
 
 
GEMS 
Cluster 
Lower 
boundary 
of total 
As* (μg/kg 
bw/ day)
a
 
Upper 
boundary 
of total 
As* 
(μg/kg 
bw/day) 
Lowest 
boundary of 
inorganic 
arsenic
b
 
(50% 
bioavailable) 
(μg/day)^ 
Upper 
boundary of 
inorganic 
arsenic
c
 (100% 
bioavailable) 
(μg/ day)^ 
Range of 
inorganic 
arsenic 
exposure via 
rice and rice 
products 
(μg/ day) 
Population 
mid-2012 
(millions)
#
 
 
A 0.91 1.26 4.8 53.4 0.92 to 6.95 302.5 
B 2.87 3.47 10.37 108.35 0.32 to 2.41 224.9 
C 1.38 1.79 9.09 85.46 0.95 to 7.22 263.7 
D 1.32 1.72 6.71 66.95 0.33 to 2.53 408 
E 1.41 1.83 5.75 63.45 0.13 to 0.97 339.2 
F 1.84 2.19 5.25 57.27 0.13 to 0.97 26.7 
G 2.08 2.42 7.82 75.14 3.79 to 28.78 3544.5 
H 1.15 1.55 6.44 66.54 0.65 to 4.9 213.5 
I 0.87 1.18 5.02 52.2 0.38 to 2.9 256.8 
J 0.97 1.28 5.01 51.88 0.75 to 5.67 357 
K 1.04 1.48 6.6 66.13 2.39 to 18.19 335.7 
L 2.69 3.05 7.88 79.1 3.84 to 29.1 307.4 
M 1.35 1.83 6.44 70.56 0.35 to 2.64 436.8 
 
Data adapted from GEMS/Food Consumption Cluster Diets database (FAOSTAT 2006) 
¥ 
Listing of countries within each cluster is available at 
http://www.who.int/foodsafety/chem/gems/en/index1.html. 
a
 Assuming 60 kg body weight per individual 
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b
 Lower bound for inorganic arsenic content assumes Non detect equals zero 
c
 Upper bound for inorganic arsenic content assumes non-detect equals the limit of detection  
* Calculations based on Table 13, FAO/WHO JECFA Monographs 8, 2011 for range of total 
arsenic content in food items.  
^ Calculations based on Table 15, FAO/WHO JECFA Monographs 8, 2011 for range of mean % 
inorganic arsenic content in food items.  
# Data source: “Population Data sheet 2012” by the Population Reference Bureau 
(www.prb.org). PRB has derived the data from International Programs Center of the US Census 
Bureau; the United Nations (UN) Population Division; the Institut national d’etudes 
démographiques (INED), Paris; and the World Bank.  
 
 
 
Table 10 - Global burden of cancers caused by foodborne arsenic 
 
 
Cancer Male Female 
Total burden (global) by 
foodborne arsenic 
Bladder 4,527 to 46,420 7,096 to 72,756 9,129 to 119,176 
Lung 4,913 to 50,373 6,931 to 71,069 11,844 to 121,442 
Skin 
(Non melanoma) 
5,365 to 55,007 5,365 to 55,007 10,730 to 110,014 
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Table 11 - Annual expected burden of cancers caused by foodborne arsenic, by GEMS 
cluster and gender, lower bounds (LB) and upper bounds (UB)
a
  
 
 
GEMS 
cluster 
Bladder cancer Lung cancer Skin cancer 
 Male Female Male Female Male Female 
 LB UB LB UB LB UB LB UB LB UB LB UB 
A 195 2001 306 3137 212 2172 299 3064 231 2371 231 2371 
B 145 1488 227 2332 157 1614 222 2278 172 1763 172 1763 
C 170 1744 267 2734 185 1893 260 2671 202 2067 202 2067 
D 263 2699 413 4230 286 2929 403 4132 312 3199 312 3199 
E 219 2244 343 3517 237 2435 335 3436 259 2659 259 2659 
F 17 177 27 277 19 192 26 270 21 209 21 209 
G 2287 23449 3584 36753 2482 25446 3502 35901 2710 27787 2710 27787 
H 138 1412 216 2214 149 1533 211 2162 163 1674 163 1674 
I 166 1699 260 2663 180 1843 254 2601 196 2013 196 2013 
J 230 2362 361 3702 250 2563 353 3616 273 2799 273 2799 
K 217 2221 339 3481 235 2410 332 3400 257 2632 257 2632 
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L 198 2034 311 3187 215 2207 304 3114 235 2410 235 2410 
M 282 2890 442 4529 306 3136 431 4424 334 3424 334 3424 
Total 4527 46420 7097 72756 4913 50373 6932 71069 5365 55007 5365 55007 
 
a
Assuming 70 years life span per individual 
 
 
 
 
 
 
Figure 5 - Annual expected burden of cancers caused by foodborne inorganic arsenic, by 
GEMS cluster and sex, lower bounds (LB) and upper bounds (UB) in males 
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Figure 6 - Annual expected burden of cancers caused by foodborne inorganic arsenic, by 
GEMS cluster and sex, lower bounds (LB) and upper bounds (UB) in females 
 
 
 
Correction of cancer burden estimates for age 
The estimates for global burden of cancers attributable to foodborne arsenic are expected to 
reflect the age distribution for the incidence of these cancer types in general. Arsenic is not an 
independent carcinogen, rather it is a co-carcinogen requiring other genotoxic events to initiate 
cancer. It is known to enhance cancer progression. As such, being exposed to arsenic might 
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predispose an individual to develop cancer upon a subsequent or simultaneous exposure to a 
potential carcinogen. Human exposure to environmental toxins gradually accumulates with the 
progression of age and this is expected to apply to foodborne arsenic as well.  
Age has a powerful influence on the risk of cancer, so age-standardization is necessary when 
comparing several populations that differ with respect to age. An age-standardized rate (ASR) is 
a summary measure of the rate that a population would have if it had a standard age structure 
(Globocan, 2008). Age-standardized world incidence/mortality estimates for cancers were 
obtained from the Globocan database which is a part of the section of cancer Information (CIN) 
of IARC. In Globocan, the ASR is calculated using 10 year age-groups. For bladder and lung 
cancers, data on age-standardized rates (per 100,000) for both genders depicts that the incidence 
rate increases with an increase in the age groups of the population. The ASR values increase for 
both lung and bladder cancers in the age groups above 55 years. Morales et al. (2000) note in 
relation to standard mortality rates of cancers that: ”There is no observed tendency in SMRs with 
respect to age, which suggests no age dependency on the risk ratio.” 
The calculations of age-specific onset of disease caused by arsenic exposure would ideally 
require epidemiological data with age-specific incidence by dose. Gibb et al. (2011) suggested 
that additional follow-up of the northeastern Taiwanese cohort and the HEALS cohort in 
Bangladesh could provide this crucial piece of information for future analysis. 
For the current analysis of age-specific incidence of bladder and lung cancers, data was adapted 
from Morales et al. (2000), Table 2 (reproduced in Appendix B) that provides a comparison of 
population data from all of Taiwan and southwestern Taiwan, with sex and age-wise distribution 
of the person years at risk (PYR) and mortality due to bladder, lung and liver cancers. This data 
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can be used to find age-distribution for arsenic-induced bladder and lung cancers because all 
Taiwan and southwestern Taiwan have populations that are almost identical in all respects except 
for differences in exposure to arsenic in drinking water. The data from Morales et al. (2000) was 
used to assess the differences in age-distribution of occurrence of bladder and lung cancers in the 
two populations from all Taiwan and southwestern Taiwan. As the values of PYR in each age 
group are different for all Taiwan and southwest Taiwan, these values were normalized such that 
the total is equal to 100. The differences in age distribution of total bladder and lung cancer cases 
were then calculated to estimate the age-specific burden by arsenic. Table 12 depicts the 
estimates of the annual number of arsenic-induced bladder and lung cancer cases per age group. 
For non-melanoma skin cancer, data was adapted from Tseng (1977) Table 1 (reproduced in 
Appendix A) that details the age-specific and sex-specific prevalence rate for skin cancer in 
southwestern Taiwan. The percentage-wise distribution of NMSC cases due to arsenic was then 
computed by normalizing the values from the column “number of cases per 1000” for males/ 
females such that the total is 100 (Table 13).  
Global estimates of age-specific incidence of expected additional cases of bladder cancer, lung 
cancer and skin cancer from foodborne inorganic arsenic exposures per year are presented in 
Table 14. Figures 2 and 3 present the age-specific incidence for bladder, lung and skin cancer 
cases due to arsenic in food in males and females respectively. 
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Table 12 - Relationship of age and sex to additional annual bladder and lung cancer cases 
attributable to arsenic 
 
 
Sex, 
age 
 
(years) 
Bladder cancer 
 
Lung cancer 
 
All Taiwan 
 
SW Taiwan 
Additional 
cases in SW 
Taiwan 
compared to 
All Taiwan 
(Normalized) 
 
All Taiwan 
 
SW Taiwan 
Additional 
cases in SW 
Taiwan 
compared to 
All Taiwan 
(Normalized) 
 
Males 
20-25 0.0 0.0 0.2 0.0 0.1 0.8 
25-30 0.0 0.1 0.5 0.1 0.2 2.1 
30-35 0.0 0.1 0.1 0.2 0.3 2.9 
35-40 0.1 0.2 0.5 0.3 0.4 1.4 
40-45 0.4 0.5 1.9 0.7 0.8 4.5 
45-50 0.7 0.9 4.0 1.4 1.7 7.1 
50-55 1.2 1.6 4.9 2.9 3.3 10.2 
55-60 1.9 2.3 5.4 5.5 6.0 15.1 
60-65 4.3 5.2 12.4 9.3 9.9 17.8 
65-70 7.7 9.1 18.2 13.9 14.3 10.0 
70-75 12.8 15.3 31.4 17.2 17.9 19.50 
75-80 19.3 20.8 20.5 17.5 17.8 8.6 
80-85 23.1 19.0 0 17.1 15.6 0 
85+ 28.5 
24.9 
 
0 13.8 11.9 0 
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Females 
20-25 0 0 0 0.1 0.8 6.9 
25-30 0.0 0.1 0.6 0.1 0.3 1.6 
30-35 0.0 0 0 0.3 0.4 0.9 
35-40 0.1 0.1 0.4 0.7 1.0 3.1 
40-45 0.4 0.6 1.4 1.4 1.9 5.0 
45-50 0.9 1.0 1.1 2.2 3.1 7.8 
50-55 1.9 3.1 9.7 3.6 5.1 13.0 
55-60 4.0 5.5 13.2 6.3 7.8 14.3 
60-65 6.3 9.9 32.6 9.5 12.3 25.5 
65-70 9.3 11.3 17.6 13.2 14.2 9.3 
70-75 14.1 16.7 23.3 15.4 16.8 12.6 
75-80 20.1 17.7 0 17.2 16.4 0 
80-85 21.3 17.9 0 16.5 14.2 0 
85+ 21.4 16.0 0 13.5 6.6 0 
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Table 13 - Expected percent of non-melanoma skin cancer cases attributable to arsenic, by 
age group 
 
 
Age 
(years) 
Males Females 
Per 1000 
Percent of 
cases due to 
arsenic (by 
age-group) 
Per 1000 
Percent of 
cases due to 
arsenic (by 
age-group) 
0-19 - 0 - 0 
20-29 1.0 0.2 1.1 0.7 
30-39 9.7 2.1 1.5 0.9 
40-49 25.9 5.7 8 5.3 
50-59 80.8 17.8 28.9 19.2 
60-69 124.8 27.6 57.0 37.9 
70+ 209.6 46.4 53.8 35.8 
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Table 14 - Annual expected age-specific incidence of bladder and lung cancers caused by 
foodborne arsenic compared on the basis of gender and range of exposure 
 
 
Age 
(years) 
Bladder cancer Lung cancer 
Males Females Males Females 
LB UB LB UB LB UB LB UB 
20-25 9 91 0 0 37 383 479 4909 
25-30 21 214 27 434 105 1080 107 1100 
30-35 3 33 0 0 141 1445 63 643 
35-40 22 222 19 302 70 713 213 2189 
40-45 90 922 65 1022 222 2274 348 3568 
45-50 182 1865 52 828 350 3585 541 5552 
50-55 223 2286 444 7017 501 5132 903 9261 
55-60 243 2498 609 9632 742 7608 992 10172 
60-65 562 5763 1502 23739 875 8974 1769 18134 
65-70 824 8455 811 12823 489 5015 641 6571 
70-75 1421 14571 1073 16959 958 9823 875 8970 
75-80 927 9500 0 0 423 4341 0 0 
80-85 0 0 0 0 0 0 0 0 
85+ 0 0 0 0 0 0 0  
Total 4527 46420 4602 72756 4913 50373 6931 71069 
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Table 15 - Annual expected age-specific incidence of non-melanoma skin cancers caused by 
foodborne arsenic (gender and range of exposure) 
 
 
Age 
(years) 
Non-melanoma skin cancer 
Males Females 
LB UB LB UB 
0-19 0 0 0 0 
20-29 12 122 12 122 
30-39 115 1181 115 1181 
40-49 308 3153 308 3153 
50-59 959 9837 959 9837 
60-69 1482 15195 1482 15195 
70+ 2489 25519 2489 25519 
Total 5365 55007 5365 55007 
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Figure 7 - Males: Age-specific incidence for bladder and lung cancer cases due to arsenic in 
food 
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Figure 8 - Males: Age-specific incidence for non-melanoma skin cancer cases due to arsenic 
in food 
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Figure 9 - Females: Age-specific incidence for bladder and lung cancer cases due to arsenic 
in food 
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Figure 10 - Females: Age-specific incidence for non-melanoma skin cancer cases due to 
arsenic in food 
 
 
4.4 DISCUSSION 
Using quantitative risk assessment, this research estimated the increased incidence of cancers 
that can be attributed to arsenic in food. The most challenging aspect was estimating the highly 
variable levels of inorganic arsenic in the varied foods consumed by the different populations 
contained in the GEMS clusters. There is uncertainty in whether arsenic in food is equivalent to 
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arsenic in water for disease promotion given the many other food constituents, such as folate 
(Hall et al., 2012) and selenium (Chen et al., 2007) that may modulate arsenic pathogenesis. The 
assumption of linear dose-response relationships of arsenic-related cancers is controversial, 
particularly regarding the mode of carcinogenicity of skin cancer, despite the EPA IRIS 
derivation of a single slope factor for arsenic-related skin cancer (USEPA IRIS, 1998). There are 
no studies that present the effects of low dose arsenic exposures on skin cancer, which reduces 
certainty regarding the shape of the lower end of the dose-response curve. Thus it is conservative 
to default to the linear model for determining the skin cancer potency factor. Accounting for 
these uncertainties, this dissertation estimates that levels of inorganic arsenic found in food cause 
a low but significant increase in the burden of lung, bladder, and non-melanoma skin cancers 
worldwide.  
Much of the available data on disease risk come from studies of arsenic in drinking water and 
often the populations studied have been exposed to higher levels of arsenic (>100 g/L drinking 
water). As levels of arsenic in water decrease, the contribution of arsenic from food to total 
arsenic exposure becomes greater and more significant (Kile et al., 2007; Kurzius-Spencer et al., 
2014). While human biomarkers for arsenic exposure (such as arsenic and metabolite levels in 
urine, blood, hair, or nails) are available (Kurzius-Spencer et al., 2014), it is not possible to 
determine the proportion of the measurements attributable to arsenic in drinking water or food. 
For the purposes of estimating human health consequences associated with arsenic consumption, 
knowing the overall population arsenic exposure matters more than knowing the relative 
contribution from different routes of exposure. For the purpose of recommending interventions, 
it can be helpful to understand the separate contributions. 
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There are several additional unavoidable constraints with estimating health risks from arsenic in 
food. The bioavailability of arsenic in different foods varies with the food group or method of 
processing and the complexity of influence of other food constituents on arsenic toxicity and 
adverse health effects. The author focused the exposure estimates and risk characterization on 
both the range of inorganic arsenic content and the range of predicted bioavailability of inorganic 
arsenic in different foods. This approach is limited to using the GEMS cluster data for food 
consumption, since it contains an inherently broad range of dietary variations between the 
countries within each cluster (Liu et al., 2010). For example, the daily consumption of rice in 
Bangladesh (GEMS cluster G country) was reported as 445g/day (Meharg et al., 2009), even 
when the average rice consumed daily for GEMS cluster G is 380g. Using the cluster values may 
underestimate the arsenic exposure via rice in Bangladesh; on the other hand, while the actual 
daily consumption overall for cluster M is 35g/day, for the USA (GEMS cluster M country) it is 
18 g (Meharg et al., 2009). One of the major assumptions in the current analysis is that the 
speciation and arsenic content of rice cultivated in different regions of the world would be the 
same. Nevertheless, there are conflicting reports indicating a large variation in the levels of 
inorganic arsenic in rice from developing and developed countries (Meharg et al., 2009; Carey et 
al., 2011). In order to overcome these limitations and obtain a realistic estimate for inorganic 
arsenic levels, the author used data from studies that provide actual measured levels (EFSA, 
2009) in different categories of food items (Schoof et al., 1999; Muñoz et al., 2001; Diaz et al., 
2012). 
The GEMS cluster data do not provide specific details of the consumption of certain 
miscellaneous food items with reported high levels of inorganic arsenic (e.g., seaweed hijiki and 
edible algae (EFSA, 2009) Table 2, miscellaneous items). In certain Asian countries, such as 
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Japan, the consumption of seaweed is a relatively important part of diet and can add substantially 
to the daily exposure levels of inorganic arsenic (JECFA, 2011; Uneyama et al., 2007). 
Despite the complexity of assessing foodborne arsenic exposures, the estimates for global burden 
of cancers caused by the estimated range of exposures appear feasible. The research presented 
here found that human exposures to inorganic arsenic through food is substantial (see Table 8) 
and can be roughly comparable with lower levels of arsenic in drinking water. It was reasonable 
to convert the data from that of Morales et al. (2000) to dietary consumption and calculate the 
slope factors for lung and bladder cancers to estimate the risk of foodborne inorganic arsenic. 
This data set reduces the concern about issues of low-dose extrapolations of arsenic’s 
carcinogenic effects, although the estimates would be improved by including additional 
epidemiological studies that focus on low dose consumption.  
The review by Gibb et al. (2011) emphasized the need for such studies on bladder and lung 
cancer that address adequacy of the sample size, as well as the synergistic relationship of arsenic 
and smoking, duration of arsenic exposure, age when exposure began and ended and the 
histologic subtype of cancer. They observed that many recent studies that examine the risk ratio 
of bladder cancer from low arsenic concentration (<100μg/L) drew cases and controls from 
arsenic-endemic areas that may reduce the difference in arsenic exposure, requiring a larger 
sample size to determine whether an excess risk exists for a given exposure. The potential for   
smoking to confound the risk estimates attributable to dietary arsenic exposure would likely be 
true for lung cancer estimates as well. The exposure misclassification further reduced the 
difference between groups and epidemiological studies focused on low-arsenic levels have a 
greater need to control for confounders (Gibb et al., 2011). 
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The estimated global burden for arsenic-induced bladder and lung cancers is the highest for both 
males and females in cluster G for several reasons. Firstly, cluster G comprises of countries in 
Asia where the arsenic content in the bedrock ranks among the highest in the world. This 
translates into high overall rate of exposure to arsenic through more than one route of exposure 
and on a consistent basis for an extended period- thus pre-disposing this population to develop 
arsenic-induced cancers. Secondly, rice is the main food consumed in most of the countries in 
Cluster G. Table 3 shows that rice contributes up to 68.1% of inorganic arsenic exposure in 
cluster G countries. Related to the first reason or type of cultivar, rice grown in cluster G 
contains higher levels of arsenic than rice grown elsewhere (Meharg et al., 2009; Carey et al., 
2012). Finally, the population size is a chief component in the model for the estimation of the 
disease burden. Cluster G comprises nearly 50% of the world population, including China and 
India. Therefore, although the percentage of arsenic via rice is high in cluster L countries as well 
(up to 65.8%), it does not reflect in a high global burden of disease for this cluster owing to its 
small population size. 
In conclusion, the results of this quantitative risk assessment indicate that consumption of arsenic 
in food increases the risk of bladder, lung and skin cancer. There are limitations with the 
estimates that are derived from the ranges of arsenic content in food and the interactions of 
arsenic with other foodborne constituents. Nonetheless, the risk estimates are valuable for 
informing policies to reduce the global burden of disease from arsenic exposures in food.  
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5.0  GLOBAL BURDEN OF DISEASE FOR CORONARY HEART DISEASE 
CAUSED BY ARSENIC IN FOOD 
5.1 ABSTRACT 
Cardiovascular disease, especially coronary heart disease (CHD), is one of the most prominent 
non-cancer disease risks clearly linked to environmental arsenic exposures. The cardiovascular 
effects of oral arsenic exposure are a global public health concern causing disease in millions of 
people worldwide. As the levels of arsenic in water become universally regulated, the exposure 
through food sources becomes critical in promoting disease development. This research 
estimates a reference dose for arsenic-induced CHD and provides an estimated burden of 
coronary heart disease due to inorganic arsenic exposure through food. A range of inorganic 
arsenic content in food for different parts of the world was estimated earlier using World Health 
Organization estimates of food consumption in thirteen country clusters and the arsenic content 
measurements of different food items reported in literature. A benchmark dose was derived from 
a relevant study in mice of arsenic-induced atherosclerosis, the main clinical driver of CHD. 
Reference doses for dietary arsenic intake and CHD and atherosclerosis were developed. The 
benchmark dose for CHD was also used to estimate the additional burden of disease for CHD 
attributable to arsenic in food. These estimates indicate that foodborne arsenic exposure poses a 
significant risk and may contribute to global burden of coronary heart disease in humans at the 
upper boundaries of arsenic exposure from food. 
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5.2 INTRODUCTION 
Oral exposure to inorganic arsenic through water and food is a prominent global health problem 
(EFSA, 2009). The risk for cardiovascular diseases has been observed to increase in areas with 
high arsenic levels in drinking water (Moon et al., 2012). Given the high burden of 
cardiovascular disease worldwide, cardiovascular disease is likely to be the most important non-
cancer disease risk posed by environmental arsenic exposures (NRC, 2013). Limited studies exist 
for cardiovascular effects of low to moderate arsenic levels (<150 μg/L in drinking water). The 
absence of strong prospective studies, limitations in assessment of exposure and outcome and 
incomplete details on cardiovascular risk factors have been major concerns with a number of 
studies (Navas-Acien et al., 2005; Moon et al., 2013). The Strong Heart Study designed to obtain 
clinical data on cardiovascular disease in Native Americans was successful in determining the 
lower end of the dose response relationships for arsenic-promoted CHD incidence and mortality 
(Moon et al., 2013).  
High arsenic content in drinking water is undeniably the most important route of exposure in 
many parts of the world. Until recently little research was focused on food components as a 
potential source of arsenic exposure. There has been an increasing interest in analyzing the 
harmful health effects of foodborne arsenic with increasing evidence about the tendency of 
dietary components (e.g. rice) to accumulate arsenic from soil and irrigation water. Since rice is a 
dietary staple in many parts of the world, its arsenic content only adds to the public health 
significance of such exercises. Global food trade also necessitates such research because 
anybody can be at the risk of exposure to arsenic from food cultivated with high arsenic content 
in the opposite corner of the world.  
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CHD refers to the disease of the coronary arteries and the resulting complications of myocardial 
infarction, angina, and ultimately cardiac death. Most clinical manifestations of CHD are caused 
by atherosclerosis. The objective of the research presented here was to use BMD analysis to 
estimate the global burden of foodborne arsenic-induced coronary heart disease. Global burden 
of disease due to specific toxicant exposure provides key information to policy formulators for 
making knowledge-based decisions on the most effective means to reduce or prevent disease. 
This research provides reference dose values for arsenic in food to determine the relative risk of 
CHD from food, as well as BMD values that lead to estimation of additional cases of CHD in 
different parts of the world consuming different amounts of arsenic in foods. This research work 
contributes towards providing a comparison of BMD values for CHD based on epidemiological 
and animal data for atherosclerosis. 
5.3 METHODS 
As described in Chapter 2, BMD modeling was used to define a point of departure that is largely 
independent of study design. BMD was estimated by the fitting of various mathematical models 
to the observed data using USEPA BMD software. The current version of the USEPA BMD 
software (version 2.4) is more suitable for analyzing animal studies. Animal data avoid issues 
with confounding variables. Conventionally it is less common for the derivation of BMD to be 
based on epidemiological data primarily because for many compounds, epidemiological studies 
of adequate quality are not available. For arsenic, recent epidemiologic literature was reviewed 
to identify strong epidemiological studies that provide dose-response information that was 
adjusted for the main potential confounding factors associated with CHD.  
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5.3.1 Studies selected for BMD calculation 
This section has been described in part in the Chapter 2 on Methods with the exception of the 
detailed methodology for primary data on mouse studies, which is presented here. 
In Vivo Mouse Exposure and Atherosclerotic Lesion Characterization 
The mouse exposure studies and assessment of atherosclerotic plaques were conducted by Dr. 
Maryse Lemaire in the laboratory of Dr. Koren Mann (Lady Davis Institute for Medical 
Research, McGill University, Montreal, Canada). The exposures were performed in agreement 
with the respective institutional guidelines for animal safety and welfare under the supervision of 
the McGill Animal Use Committee. Male ApoE
-/-
 mice (Taconic Farms, Hudson, NY) (5 weeks 
old, n ≥ 5) were either maintained on tap water or on tap water-containing sodium meta-arsenite 
(NaAsO2) (Sigma, MO). The ApoE
-/-
 mouse model was used because these mice develop 
atherosclerotic plaques, in contrast to wild-type mice, providing a validated tool for 
atherosclerosis research. Atherosclerotic lesion formation was examined en face in the aortic 
arch and in cross-sections of the aortic sinus. Mice that received NaAsO2 were exposed to 
arsenic ranging from 10 ppb to 200 ppb (0.35 mg/l NaAsO2) for 13 weeks. This exposure is 
representative of a human drinking moderate to highly arsenic contaminated water for 5-8 years. 
Solutions containing NaAsO2 were refreshed every 2–3 days to minimize oxidation to As(V).  
The entire aorta, from the heart to the iliac arteries, was removed and rinsed with PBS and fixed 
in 4% paraformaldehyde. Periadventitial tissue was removed and the aorta was cut 
longitudinally. The aortic surface was stained en face with oil red O (Electronic Microscopy 
Sciences, PA). Lipid staining is not necessary for quantification of atherosclerotic lesions, but it 
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can be useful in assessing the disease when lesions are small (Daugherty et al., 2003). Percentage 
of lesion area of the aortic arch, as defined as the region from ascending arch to the first 
intercostal arteries, was evaluated with the Infinity Analyze software 5.0 (Lumenera, Canada). 
The heart was removed, rinsed, fixed in 4% paraformaldehyde and incubated overnight in a 30% 
sucrose solution (Braun et al., 2003). The tissues were frozen then in Tissue Tek OCT (Sakura, 
CA) reagent, and serial cryosections of 6m thickness were cut from the origin of the aortic root 
throughout the aortic sinus. 5 to 7 sections per animal were stained with oil red O and the mean 
lesion area was calculated using ImageJ software (National Institute of Health). Percentage of 
lesion area was evaluated relative to the total aortic sinus area. The lipid content and the collagen 
content of the plaque were evaluated with ImageJ, using their specific stains (oil red O and 
picrosirius red (Polysciences, PA), respectively). 
Goodness of Fit test statistics 
No model was determined to be the most biologically plausible for the endpoints that were 
considered. All models were found to describe the data well, based on the comparison of p-value 
(> 0.1); however, the Weibull and Gamma models failed to generate a plot. The best-fitting 
model for dichotomous data was selected consistent with the USEPA Benchmark Dose Technical 
Guidance Document (USEPA BMDS, 2012) from the models exhibiting adequate fit, as follows. 
If the BMDL estimates from the models exhibiting adequate fit were within a range of two- to 
threefold, then the model with the lowest AIC was selected. If the range of BMDLs is larger than 
two- to threefold (indicating that some model dependence is assumed), then the model with the 
lowest BMDL is selected.  
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Choice of benchmark response (BMR) 
BMD approach begins by identifying a criterion for adverse effect. In most analyses, the 
criterion for adverse effect has been the manifestation of disease in a non-exposed population. 
BMD is defined as the level of exposure that will increase the risk of disease by a pre-specified 
amount. This increase is referred to as the benchmark response (BMR) (Jacobson et al., 2002). 
For BMD analysis of the epidemiological data, BMR of 1% was selected as it would generate a 
BMD for an increase of 1% in the disease rate. This would provide a conservative estimate of 
any increase in disease in the general population over the non-exposed population. For the mice 
data, a change in the mean equal to one control standard deviation from the control mean was 
used as BMR, since there is no other over-riding reason for defining an alternative BMR. BMR 
of one standard deviation (SD) gives an excess risk of approximately 10% for the proportion of 
individuals below the 2nd percentile or above the 98th percentile of controls for normally 
distributed data. Therefore BMD1.0SD is the profile-likelihood-based dose for which the response 
equals a predicted mean one standard deviation below the predicted control mean.  
Computation of BMD 
Epidemiological data - 
In order to derive a relevant daily dose of oral arsenic exposure, the biomarker levels first needed 
to be converted into unadjusted urinary arsenic levels using the levels of creatinine (Cr) reported 
for the population cohort studied in the Strong Heart Study, 1.22 g/L of urine (Navas-Acien et 
al., 2009). A number of epidemiological studies found a near-perfect correlation between the 
levels of arsenic in drinking water and the levels in urine of individuals drinking the water, when 
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there was greater than 100 ppb arsenic. For example, a 97% correlation between water arsenic 
levels and the urinary arsenic levels was reported for a study cohort in Chile (Smith et al., 2009). 
The relationship becomes non-linear at lower water arsenic levels when the individual is 
consuming arsenic in food (Kile et al, 2007); however it was assumed that urinary levels would 
directly reflect intake. LogLogistic model was adjudged to be the best fit (as described in the 
following section) and the corresponding BMD1 value (19.74 μg/g Cr) was selected as the 
representative BMD1. The equivalent BMD for oral arsenic exposure was calculated as:  
BMD1 (μg/l)= [19.74 (μg/ g Cr) * 1.22 (g Cr/ l) / 0.97] 
= 24.83 (μg/L) 
Mouse data – 
The BMD1.0SD generated by the BMD software for model Exponential 4 was used. This BMD 
value from mouse study was based on a low to moderate daily dose of oral arsenic exposure 
(ranging from 10 ppb to 200 ppb). 
BMD1.0SD= 36.61 (μg/L) 
Conversion factor for mouse data to human equivalent BMD value –  
An average adult lab mouse weighs approximately 25 gms and consumes 3.7 mL water per day. 
Hence per unit body weight the water consumption for a lab mouse is 0.148L/kg/ day. As a 
comparison, an adult human being drinks 2L water per day and has an average weight of 60 kgs 
or 0.033 L/kg/ day consumption of water per unit body weight. Thus a mouse drinks (4.48) times 
more water per unit body weight. This conversion factor would be different if the average body 
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weight for an adult is assumed to be 70 kg or 80 kg. The consumption rate of water per unit body 
weight would be (0.029 L/ kg/ day) and (0.025 L/ kg/ day) respectively. These would then 
denote that per unit body weight, a lab mouse drinks (5.1) or (5.92) times more water than a 
human being.  
5.3.2  Reference dose derivation - Including application of Uncertainty Factors 
(UFs) 
Consideration of the available dose-response data for CHD incidence and clinical endpoint 
etiology (e.g., atherosclerosis) led to the selection of the epidemiological study (Moon et al., 
2013) along with data from mouse studies (primary data from our collaborator Dr. Koren Mann 
that was analyzed for BMD analysis) as the principal studies for derivation of RfD. Based on 
epidemiological data, BMD1 of 19.0546 (g/g Cr) (LogLogistic model) was selected as the POD 
for derivation of the chronic RfD. Another RfD was derived from mouse data by using BMD1.0SD 
of 36.6051 ppb (Exponential 4 model) as the POD. 
The general formula for calculating the RfD was: 
RfD = [BMD (g/L)*(daily water consumption)]  (Average body weight)  Uncertainty 
Factors) 
The EPA addresses how to derive a reference dose in A Review of the Reference Dose and 
Reference Concentration Processes (U.S. EPA, 2002; Section 4.4.5), which defines uncertainty 
factors of concern. The guidelines address 5 areas of uncertainty that can reduce the observed 
BMD or reference dose where there is no risk of disease by several orders of magnitude. 
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Uncertainty factors are divided into the reference dose to provide a margin of safety depending 
on the intensity of uncertainty the values of factors can be as low as 1 (no uncertainty), 3 
(intermediate uncertainty) or 10 (high level of uncertainty). 
Uncertainty Factor Consideration for Epidemiological data 
A composite UF of 10 was applied to the selected POD to derive an RfD based on application of 
BMD analysis to epidemiological data. 
 An intra-species uncertainty factor of 10 was applied. This was due to accounting for high 
levels of variation in terms of cardiovascular disease development within human populations 
exposed to arsenic. The concern was that the Native American population analyzed in the 
SHS might not reflect the US population as a whole. In addition, factors such as sex, age, 
body mass index and smoking status account for variability of response to oral arsenic 
exposure in human populations. 
 An inter-species uncertainty factor of 1 was applied. This uncertainty factor accounts for 
uncertainty in characterizing the toxicokinetic or toxicodynamic differences between animals 
and humans following exposure to the toxicant in consideration. Use of epidemiological data 
renders this uncertainty factor inapplicable in the RfD derivation. 
 A database uncertainty factor (meant to account for database deficiency) of 1 was used. Since 
Moon et al. (2013) is a prospective cohort study that had a long and thorough follow-up 
period of about 20 years, the data used for POD analysis is considered adequate. 
 A sub-chronic to chronic uncertainty factor of 1 was used. This uncertainty factor is needed 
to account for extrapolation of data from a sub-chronic exposure to a chronic exposure. Since 
the follow up period in the cohort studied by Moon et al., (2013) is 20 years, this study was 
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considered a chronic exposure study. An exposure can be defined as chronic if it lasts longer 
than approximately 10% of an individual’s average life span. 
 A LOAEL to NOAEL uncertainty factor of 1 was used because the current approach is to 
address this factor as one of the considerations in selecting a BMR for BMD modeling. In 
this case, a BMR of 10% extra risk of mortality (due to arsenic induced coronary heart 
disease) was considered to be a minimally biologically significant level of effect. This BMR 
reflects the severity of the critical effect. 
Uncertainty Factor Consideration for mouse data 
A composite UF of 30 was applied to the selected POD to derive an RfD based on BMD analysis 
of mouse data.  
 An intra-species uncertainty factor of 10 was applied. The mouse data is derived from study 
conducted with ApoE null mice that are genetically susceptible to develop atherosclerotic 
lesions. The ApoE null mice may not represent the response of other genetic variants of 
mouse species to arsenic exposure in terms of developing atherosclerotic plaques.  
 An inter-species uncertainty factor of 1 was applied. Mice are considered very close to 
humans in toxicokinetic and toxicodynamic parameters with respect to cardiovascular disease 
(Straub et al., 2008; States et al., 2009) and the ApoE
-/-
mice responded to arsenite in a human 
relevant dose range. Therefore this factor was considered irrelevant for contributing to 
uncertainty towards calculation of RfD. 
 A database uncertainty factor (meant to account for database deficiency) of 1 was used 
because the animal study covered a broad spectrum of doses and was conducted for a long 
span of 13 weeks.  
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 A sub-chronic to chronic uncertainty factor of 3 was used. Lab mice have an average life 
span of 2-3 years. Study period extending to 13 weeks may therefore be considered to be a 
chronic exposure. In order to account for variability in the life spans of different mice 
variants, an UF of 3 was applied in this case. 
 A LOAEL to NOAEL uncertainty factor of 1 was used. In this case, a BMR level of one 
control SD was used to derive BMD.  
5.4 RESULTS 
No biologically-based models are available for arsenic induced atherosclerosis leading to 
coronary heart disease in humans. In this situation, as per EPA’s practice (USEPA n-Butanol, 
2011), a range of models was evaluated to determine the best way to empirically model the dose- 
response relationship in the range of the observed data. For mouse data, all models that 
are considered as part of USEPA’s BMDS for analysis of continuous data were considered to be 
consistent with biological processes. The Hill model was an exception as it is considered to apply 
only when the biological response has been established to be receptor mediated.  
All available dichotomous models in the EPA’s BMDS (version 2.4) were fit to the 
epidemiological datasets for the increased incidences of CHD. All the tested models except 
Weibull and Gamma were considered biologically consistent. Tables 16, 17 and 18 summarize 
the BMD modeling results for these two datasets. 
Goodness of Fit test statistics 
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LogLogistic model was considered to be the best fitting model for the CHD data based on the 
criterion for the lowest AIC value, adequate fit (p-value > 0.1) and BMDL estimates being in a 
range of two to three - folds (Table 16). For the continuous data from mouse studies, all models 
except models Exponential 2 and Exponential 3 fit the data well based upon the p- values being 
greater than 0.1 (Table 17). 
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Table 16 - BMD modeling based on CHD incidence data from Moon et al. (2013): 
Summary data for the fits of the models 
 
 
Model AIC p- value BMD1 (g/ g Cr) BMDL1 (g/ g Cr) 
Logistic 3911.17 0.35 3.52 2.23 
LogLogistic 3909.32 0.88 19.74 2.24 
LogProbit 3911.32 0.62 19.05 0.67 
Probit 3911.19 0.35 3.47 2.17 
Multistage 3910.36 0.53 8.87 2.001 
Quantal Linear 3911.31 0.33 3.21 1.83 
Weibull Error^    
Gamma Error^    
 
^ Gamma and Weibull plotters generated error reports as the number of parameters being estimated 
were greater than the number of dose groups in the data. 
 
 
 
The Exponential 2 and 3 models were not considered for further evaluation due to unacceptable 
p-values. Based on the criterion for the lowest AIC value, Exponential 4 and Exponential 5 
appear to fit the data equally well. 
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Table 17 - BMD modeling based on continuous data on surface area of atherosclerotic 
lesions in mice exposed to arsenic in drinking water: Summary data for the fits of the 
models 
 
 
 
Model Name p-value AIC 
Exponential2 0.05 106.42 
Exponential3 0.05 106.42 
Exponential4 0.44 102.35 
Exponential5 0.44 102.35 
Hill Not valid*  
Linear 0.65 104.71 
Polynomial 0.44 104.71 
Power 0.65 104.71 
 
* Hill model is consistent with the receptor-mediated response. It is not valid in this case, as the 
mechanism of arsenic induced atherosclerotic lesions is not receptor-mediated. 
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Table 18 - Observed and predicted responses for best - fit models considered: Exponential 
4 and 5 
 
 
  Response Means Response Standard Deviations Scaled Residuals 
Dose N Observed Exp 4 Exp 5 Observed Exp 4 Exp 5 Exp 4 Exp 5 
0 8 0.4625 1.07 1.07 0.9054 2.65 2.65 -0.645 -0.645 
10 5 3.05 1.79 1.79 1.21 2.65 2.65 1.06 1.06 
50 5 4.42 4.685 4.685 2.69 2.65 2.65 -0.22 -0.22 
100 6 8.25 8.303 8.303 1.475 2.65 2.65 -0.05 -0.05 
200 8 15.56 15.54 15.54 4.81 2.65 2.65 0.02 0.023 
 
 
 
 
The scaled residuals for Exponential 4 and Exponential 5 are acceptably small (<1.0) at all doses 
except 10 ppb. Comparing the values of scaled residuals of interest provides an estimate of the 
scaled difference between the observed and predicted means for the dose group that is closest to 
the calculated BMD. Exponential 4 and Exponential 5 models were selected for BMD estimation 
(Table 18) based on the above considerations. However, a formal Chi-squared test of the 
differences between the Exponential 4 and Exponential 5 likelihoods shows that one would not 
reject the hypothesis that Exponential 4 and Exponential 5 provide equivalent fits (p = 1.641). 
Exponential 4 was therefore chosen as the simplest model that gives a reasonable fit to the data. 
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Figure 11 - BMD analysis for epidemiological data: LogLogistic model with BMR of 1% 
extra risk for BMD 
X - axis represents the dose in μg/g creatinine of urinary arsenic levels. Y - axis shows the 
fraction of exposed population affected with CHD. 
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Figure 12 - BMD analysis for mouse data: Exponential 4 model with BMR of 1.0 standard 
deviation extra risk for BMD 
X- axis represents the dose in μg/L of arsenic in drinking water. Y - axis shows the fraction of 
area of the aortic arch with atherosclerotic lesions 
 
 
 
Computation of BMD 
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Epidemiological data -  
BMD1 value from the best fitting model (LogLogistic) was based on biomarker data of urinary 
levels of arsenic adjusted for creatinine.  
BMD1= 19.74 (μg/g creatinine) 
Equivalent BMD for oral arsenic exposure (as described in the Methods section) 
= 24.83 (μg/L) 
Mouse data: 
BMD1.0SD for Exponential 4 model was adjudged best- fit based on the comparison of all 
goodness of fit parameters as described in the previous section.  
BMD1.0SD = 36.61 μg/L 
Reference Dose Derivation —Including Application of Uncertainty Factors (UFs) 
RfD based on epidemiological data (Moon et al., 2013) 
Consideration of uncertainty in the human epidemiological data yielded a composite UF of 10 as 
described in the section 5.3.2. Applying the BMD1 value for epidemiological data, RfD for oral 
arsenic exposure for an average adult consuming 2L water per day, was calculated as follows 
RfD = 24.83 (μg/L) * [2 L/day]  Average adult body weight  10 
Assuming average adult body weights of 60 kg (Walpole et al, 2012), 70 kg or 80 kg to account 
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for variability, the RfD (μg/kg/day) values are presented in Table 19. 
RfD based on animal data  
Uncertainty factors, addressing five areas of uncertainty resulting in a composite UF of 30, were 
applied to the selected POD to derive an RfD based on application of atherosclerotic lesion data 
in mice. Applying the BMD1.0SD value for mouse data, and the conversion factor for mouse data 
to human data (as described in section 5.3.1), RfD for oral arsenic exposure for an average adult 
human was calculated as follows: 
RfD = [36.61 μg/L * 3.7 mL Average body weight for lab mouse  UF]  conversion factor 
= (0.18 μg/kg/day)  conversion factor 
Table 19 presents the different RfD values assuming average adult human body weights of 60 kg 
(Walpole et al., 2012), 70 kg or 80 kg to account for variability. 
 
 
  
Table 19 - Estimated RfD values for oral arsenic exposures based on epidemiological 
data and mouse data 
 
 
RfD (μg/kg/day) 
Average adult body 
weight 60 kg 
Average adult body 
weight 70 kg 
Average adult body 
weight 80 kg 
RfD (μg/kg/day)a 0.083 0.071 0.063 
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RfD (μg/kg/day)
b
 0.04 0.035 0.03 
 
a 
RfD based on Moon et al., 2013 epidemiological data 
b
 RfD based on primary data from mouse studies  
 
 
 
Calculating risk and a global burden of CHD from foodborne arsenic 
The data from dose–response and exposure assessments were integrated to quantify the burden 
of arsenic-related cancers across the world to characterize the risk of coronary heart disease due 
to foodborne arsenic. Table 9 (Chapter 4) provides the estimated range of dietary exposure to 
inorganic exposure for all the 13 GEMS clusters. The estimated range of daily dietary inorganic 
arsenic exposure was divided by the BMD1 value based on epidemiological data. This risk was 
then multiplied with the background rate of coronary heart disease in that region/country to 
estimate the increase in total number of CHD cases per year that can be attributed to dietary 
inorganic arsenic. 
As an illustration, the following are the estimates for USA. Based on similarities of dietary 
pattern, WHO GEMS 13 cluster approach (WHO GEMS, 2006) classifies USA under GEMS 
Cluster M. For this cluster, Table 9 provides 6.44 to 70.56 μg/day as the range of dietary 
inorganic arsenic exposure. It should be mentioned that the lower bound of this range (6.44 
μg/day) is highly conservative as it represents the lower estimate of total arsenic content in 
different components of the diet, as well as the lower range of inorganic content of the different 
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food categories and the lower end of the bioavailability (50%). The upper bound of arsenic 
exposure is based on the scenario that all the components of diet have the maximum detected 
total arsenic content; highest possible fraction of inorganic arsenic and the inorganic arsenic is 
100% bioavailable. All these factors contribute to the wide range of dietary inorganic arsenic 
exposure estimates for this cluster.  
Thus to calculate the potential burden of CHD from the highest exposure to arsenic in GEMS 
cluster M: 
(Upper bound estimate of bioavailable iAs in food) (μg/day)/BMD (μg/day)  
= (70.56 (μg/day)/(49.66 (μg/day) = 1.42 
Similarly, the potential burden of CHD from the lowest exposure to arsenic in the cluster would 
be: 
(Lower bound estimate of bioavailable iAs in food) (μg/day)/BMD (μg/day)  
= (6.44 (μg/day)/(49.66 (μg/day) = 0.13 
USA was selected as a representative country for this GEMS cluster M. With regard to 
incidence, data from the Atherosclerosis Risk in Communities (ARIC) and Cardiovascular 
Health Study in USA indicate that annually, 785,000 new coronary attacks occur (DeBacker, 
2009). The following algorithm was used to calculate the burden of disease due to the upper 
bound of arsenic in food: 
Risk * CHD incidence rate 
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=1.42*785,000 = 1,114,700 
This gives the worst-case scenario number of 329,750 (calculated incidence – back ground 
incidence) extra CHD cases annually attributable to foodborne arsenic exposure for a total 
population of 313.9 million in USA that assumes everyone in the USA ate the same diet every 
day. Conversely, using the risk value for the lower bound of exposure in GEMS cluster M, the 
hazard quotient falls well below 1.0 indicating that there is no increase in attributable CHD 
disease with consumption at the lower bound. As seen in Table 21, consuming food with the 
lowest bound of available inorganic arsenic content poses no increased CHD burden in all of the 
clusters. However, the risk from consuming food at the upper bound is significant in all clusters 
except clusters A and I. 
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Table 20 - Risk characterization for coronary heart disease corresponding to foodborne 
inorganic arsenic exposure at 50 - 100% bioavailability in 13 WHO-GEMS clusters of 
countries (adapted from Table 9) 
 
 
 
 
 
 
 
 
 
 
GEMS 
Cluster 
Lowest 
boundary of 
iAs (50% 
bioavailable) 
(μg/day)^ 
Upper 
boundary of iAs 
(100% 
bioavailable) 
(μg/ day)^ 
Lower bound 
estimate for risk 
characterized for 
CHD incidence 
Upper bound estimate 
for risk characterized 
for CHD incidence 
A 4.8 53.4 0.10 1.07 
B 10.37 108.35 0.21 2.18 
C 9.09 85.46 0.18 1.72 
D 6.71 66.95 0.14 1.35 
E 5.75 63.45 0.12 1.28 
F 5.25 57.27 0.11 1.15 
G 7.82 75.14 0.16 1.51 
H 6.44 66.54 0.13 1.34 
I 5.02 52.2 0.10 1.05 
J 5.01 51.88 0.10 1.04 
K 6.6 66.13 0.10 1.33 
L 7.88 79.1 0.16 1.6 
M 6.44 70.56 0.13 1.42 
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Similarly for United Kingdom, which falls in Cluster E, the upper bound estimate for risk 
characterized for CHD incidence is 1.28. The CHD statistics of the British Health Foundation 
(Scarborough et al., 2010) indicate that the average annual incidence rate of myocardial 
infarction is 800 per 200,000. For the total population of the UK in 2010 (62.3 million), the 
derived incidence would be 249, 200. Using the same algorithm, the burden of disease due to the 
upper bound of arsenic in food in the United Kingdom was 
Risk* CHD incidence rate 
= 1.28* 249, 200 
= 318,976 
Thus, for United Kingdom in the worst-case scenario 69, 776 (calculated incidence – back 
ground incidence) extra CHD cases per year can be attributed to foodborne arsenic exposure. 
Assuming that in the UK regardless of age, and sex, everybody ate essentially the same diet, 
arsenic in food can cause an increase of 28% in CHD incidence over the background rate. While 
in USA, it can cause upto a 42% increase in incidence over the background. However this 
increase accounts to only about 0.1% of the total populations of the two countries individually, 
indicating that even in the worst case scenario, the risk is significant but not overwhelming. 
5.5 DISCUSSION 
Using quantitative risk assessment approach, the reference dose for foodborne inorganic arsenic 
induced CHD was derived. This research used BMD analysis to conduct dose-response 
 122 
assessment for coronary heart disease, a major non-cancer disease endpoint due to arsenic 
exposure (NRC, 2013). BMD analysis is well suited for risk assessments based on dichotomous, 
as well as continuous data, from exposure studies, although it is often difficult to identify 
discrete dose-response thresholds in the latter.  
USEPA BMD software does not have the ability to factor in adjustments made for confounders 
like age, sex, smoking and other socio-demographic factors that are epidemiologically 
significant. Therefore, primary data from mouse studies was analyzed and applied to BMD 
modeling to provide a comparison to the BMD values generated from epidemiological data. In 
this analysis, the RfD was calculated using BMD values instead of BMDL. BMDL is the 
statistical lower confidence limit on the dose or concentration at the BMD, and provides a 
conservative estimate of the dose that can cause a predetermined increase in adverse effect. Thus 
it is conservative to default to BMD instead of BMDL for estimating a safe dose of arsenic in 
food. Also, the estimated BMD for 1% BMR is very close to the observed significant increase in 
the hazard ratios for coronary heart disease incidence reported in the Strong Heart Study (Moon 
et al., 2013). The BMD1 value of 19.74μg/g Cr (urinary arsenic levels) derived here corresponds 
to the hazard ratio of 1.2 in a study cohort of 3575 individuals (Moon et al., 2013), 
corresponding to approximately 15% of the exposed participants for coronary heart disease 
incidence.  
The estimated RfD derived from animal data is more conservative than the RfD for 
epidemiological data. This might be attributed to the fact that the animal data uses atherosclerotic 
lesions as the observed endpoint. Although atherosclerosis is the underlying pathology of most 
clinical manifestations of coronary heart disease, it is pre-clinical evidence and more people will 
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have plaques than will advance to CHD. The conversions used to derive equivalent BMD values 
for humans are based on inter-species conversions for amount of daily water consumption per 
unit body weight difference between mice and humans. Despite the progress that has been made 
toward prevention and cure of coronary heart disease, it appears that actual abilities are limited to 
a retardation of atherosclerosis and a postponement of CHD to older age (DeBacker, 2009). 
Given the demographic changes that are taking place in most communities, further increase in 
the absolute number of people with CHD is expected. Most of the available data on risk of CHD 
from arsenic are based on studies of high levels of arsenic in drinking water. Limited numbers of 
studies provide exposure information at low to moderate levels of arsenic exposure. Another 
limitation in analysis of burden of CHD is that most of the studies and databases report the 
mortality data for CHD on a country/ WHO region level. This makes it difficult to translate the 
estimate of risk to annual additional cases of CHD expected due to arsenic exposure through 
food. Also, the incidence of CHD is age-specific, but the estimates for dietary arsenic induced 
burden of CHD for USA presented here are an overall estimate inclusive of all age groups.  
The research framework presented here enables assessment of the additional burden of coronary 
heart disease due to inorganic arsenic exposures through food. It should be noted that while the 
estimates for USA represent the additional disease burden, this number does not reflect 
additional risk for entire US population. This is because the upper bound estimate of  foodborne 
inorganic arsenic that is bioavailable is realistic for only a small portion of the US population 
whose entire diet corresponds to high arsenic content. The possible dissimilarity in diets is a 
major limitation of using the WHO-GEMS dietary cluster approach. GEMS cluster approach 
works on the major assumption that the individuals within each GEMS cluster consume roughly 
comparable amounts of the foodstuffs that are presented in the GEMS database. This applies  
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across age groups and genders. On the other hand, if the exposure from water is also brought 
under consideration, then the risk of arsenic induced coronary heart disease would be somewhat 
higher than these estimates.   
The expected burden of disease attributable to foodborne arsenic is a function of the baseline risk 
to CHD in the population being studied. So any additional estimates are influenced by the pre-
existing incidence of CHD in that population. The estimated burden of disease attributable to 
foodborne arsenic exposure directly corresponds to the characterized risk values (Table 20) for 
CHD incidence. Additionally, the shape of the dose-response curve beyond the threshold would 
also affect the estimates of CHD incidence. It is a limitation that the current analysis does not 
allow the prediction of whether the dose response curve would be linear or non-linear beyond the 
threshold. Even with the assumption of linearity, it would not be possible to estimate the slope of 
the linear curve. However, this research is based on an assumption of linearity of the dose 
response curve beyond the threshold point with 1:1 correlation between the dose and response. 
The estimates presented in this research strongly indicate that exposure to food containing lower 
range of arsenic content is not responsible for any additional burden of CHD in any cluster or 
country worldwide. The CHD burden estimates for USA and UK presented in this research are 
within the range of observed increase in cardiovascular disease mortality (Chen et al, 2011). In 
this prospective cohort study of 11, 746 participants in Bangladesh, an increase of 22% was 
reported in the risk of mortality from cardiovascular for arsenic exposure levels of 12 ppb to 62 
(Chen et al., 2011). The range of exposure estimates for bioavailable inorganic arsenic in food 
for USA and UK (Cluster M and E respectively) is comparable (between 5.75 to 70.56 g/day) 
to the level of arsenic in drinking water associated with the level of observed increase in risk in 
Chen et al. (2011) (Table 9). It is also comparable to the ATSDR estimate of an average 
 125 
consumption of 40 g/day of arsenic across the USA (reference website).  In addition, based on a 
duplicate diet survey in Bangladesh, Kile et al. (2007) observed that the background dietary total 
arsenic intake for the population, calculated using the dietary exposures for the participants with 
no detectable arsenic in their drinking water, was 46 μg/day. This indicates that based on our 
estimated BMD1 value for epidemiological data, 49.66 μg/day, the entire study population in 
Bangladesh might be at a risk of developing CHD due to foodborne arsenic  
The relationship between biomarkers (e.g., urinary and toenail levels) and low levels of drinking 
water arsenic concentrations was found to be non-linear but becomes linear as arsenic levels in 
drinking water increase (Karagas et al., 2000; Kile et al., 2005, 2007; Watanabe, 2001). It is 
therefore likely that the added exposure from dietary sources explains the observed non-linearity 
in these relationships. This non-linearity as well as a daily consumption of 2 liters of water for an 
average adult were taken into account while deriving an equivalent oral dose of arsenic exposure 
from the estimated BMD1 based on creatinine adjusted urinary arsenic levels.  
In conclusion, the results of this quantitative risk assessment indicate that similar to what was 
found for the incidence of bladder, lung and skin cancer, the consumption of arsenic in food can 
increase the burden of CHD. This research also estimates that the risk of CHD incidence is not 
increased at the low end of exposure to foodborne arsenic. It appears that this risk occurs 
globally only when consuming food with the upper bound of available inorganic arsenic levels 
and that consumption of foods containing the lower bound of arsenic does not increase the 
burden of CHD in any cluster country. All the limitations of exposure assessment, for the ranges 
of arsenic content in food as well as other risk modifying factors that were discussed in context 
of GBD for cancers, apply to these CHD burden estimates. The risk estimates are nonetheless 
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valuable for informing policies to reduce the global burden of disease from arsenic exposures in 
food. The main policy conclusion that can be drawn is that the global burden of CHD from 
foodborne arsenic might be reduced or eliminated if foods with the lower bound of arsenic 
content are consumed. 
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6.0  CONCLUSIONS 
Multiple epidemiological studies indicate an association between arsenic exposure and an 
increased risk for bladder cancer, lung cancer and non-melanoma skin cancer (IARC, 
2012).  Cardiovascular disease may be the most important non-cancer disease risk posed by 
environmental arsenic exposures, given the high burden of this disease worldwide (NRC, 
2013). The World Health Organization (WHO) Foodborne Disease Burden Epidemiology 
Reference Group (FERG) is focused on estimating the global burden of disease from foodborne 
chemical exposures, including dietary inorganic arsenic exposure. The data presented in this 
thesis demonstrate that inorganic arsenic in food causes a significant burden of cancer, as well as 
non-cancer diseases globally. Estimates of global disease burden enable policy makers to 
prioritize the allocation of limited resources to improve public health in the most effective 
manner. Reducing the daily consumption of food containing the highest levels of arsenic (e.g., 
certain cultivars of rice) may be the most effective means of reducing the global burden of 
disease caused by foodborne arsenic.  
6.1 ESTIMATION OF GLOBAL FOODBORNE INORGANIC ARSENIC 
EXPOSURE 
The level of inorganic arsenic in different food items was abstracted from literature sources 
including recent reports by Joint Expert Committee of Food Additives (JECFA, 2011) as well 
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European Food Safety Authority Report (EFSA, 2009). To estimate the total consumption of 
food worldwide, World Health Organization Global Environmental Monitoring Systems (WHO 
GEMS, 2006) databases were utilized. WHO divides all countries of the world into 13 clusters 
based on similarities in their dietary patterns. This analysis provided a range of dietary arsenic 
exposure where the lower and upper bounds respectively denote the lowest and highest levels of 
total bioavailable inorganic arsenic content. The GEMS cluster approach has certain limitations 
including the assumption that individuals within each GEMS cluster consume roughly 
comparable amounts of the foodstuffs that are presented in the GEMS database, including across 
age-groups and sex. Moreover, it contains an inherently broad range of dietary variation between 
the countries within each cluster (Liu et al., 2010). One of the major assumptions in the current 
analysis for estimating the inorganic arsenic content for different food groups is that the 
speciation and arsenic content of foods cultivated in different regions of the world would be the 
same. The GEMS cluster data also do not provide consumption details for certain miscellaneous 
food items (e.g., seaweed) with reportedly high levels of inorganic arsenic. However, GEMS 
cluster approach does provide a uniform platform for comparing the exposure estimates for 
foodborne arsenic. Most importantly, it highlights the impact of change in dietary patterns on 
exposure to foodborne toxicants like arsenic. For example, rice is a staple diet for certain 
populations in different parts of the world and different cultivars of rice tend to accumulate 
arsenic from the soil and irrigation water to different degrees. Monitoring the levels of arsenic in 
the soils and waters where the rice is grown or planting cultivars that have relatively lower 
uptake of arsenic would help to reduce the intake of inorganic arsenic. 
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6.2 GLOBAL BURDEN OF DISEASE FOR SKIN, LUNG AND BLADDER CANCER 
CAUSED BY ARSENIC IN FOOD 
A literature review of epidemiological data associating oral arsenic exposure to bladder, lung and 
non-melanoma skin cancers in Chapter-3 provided a conclusive association of arsenic with these 
cancers. This research relied on linear extrapolation as the default conservative approach for 
dose-response assessment (USEPA, 2005) because there is insufficient information about 
the mode of action of arsenic-induced cancers. Although EPA IRIS also derived a single slope 
factor for arsenic-related skin cancer, the assumption of linear dose-response relationships of 
arsenic-related cancers is contentious (USEPA, 1998). As the majority of epidemiological 
evidence for arsenic induced disease is based on exposure to arsenic in water, it is reasonable to 
derive a slope factor based on water arsenic data from Taiwan (Morales et al., 2000). This was 
done by converting the water arsenic exposure to equivalent dietary arsenic exposures 
beforehand. The estimates presented here could not rule out the confounding of disease burden 
for lung cancer by smoking.  
The global burden of disease estimates presented in this thesis are highest for all three cancer 
types in countries that fall in GEMS cluster G. This cluster comprises of the most densely 
populated countries of the world like China, India and Bangladesh and the GBD estimates reflect 
the large population size of these countries. Indeed, other recent studies have also reported 
rapidly rising cancer incidence and high cancer mortality rates in China and India contributing to 
a major portion of global cancer burden (Goss et al., 2014; Collingridge, 2014). In addition, 
cluster G countries geographically possess high arsenic content in the bedrock thus exposing the 
population to a high overall rate of chronic arsenic exposure through more than one route of 
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exposure. All these factors can potentially pre-dispose the population to develop arsenic induced 
cancers.  However, the prevalence of arsenic in the soils and bedrock is not uniform throughout 
cluster G countries, nor are the dietary constituents (e.g., arsenic in rice) consistent across the 
entire population in the cluster.  Thus the averaging from the GEMS cluster approach may over- 
and under-estimate the true risk of cancer in a given population within the cluster. 
6.3 GLOBAL BURDEN OF CORONARY HEART DISEASE 
A recent National Research Council report concluded that cardiovascular disease are the non-
cancer diseases where incidence is most clearly correlated with environmental arsenic exposures 
(NRC, 2013). A literature review of epidemiological studies on arsenic related cardiovascular 
effects was conducted with a special emphasis on CHD. The primary pathologic process that 
underlies cardiovascular disease is atherosclerosis and it is clinically manifested as CHD, stroke, 
or peripheral arterial disease. This research applies BMD analysis approach as per USEPA 
BMDS guidelines and USEPA BMD software (version 2.4) to derive a RfD for foodborne 
arsenic induced CHD. The literature review identified the Strong Heart epidemiological study, as 
the best data set to carry into the BMD analysis (Moon et al., 2013). In this recent prospective 
cohort study, Moon et al., (2013) provided dose-response relationships for CHD incidence and 
mortality in a population exposed to relatively low levels of arsenic. The rigorous measure of 
clinical CHD endpoints combined with defining the low end of the dose response curve 
combined to demonstrate the value of using this data set to estimate disease risks from the 
relatively low amount of arsenic found in food.  Other datasets from large prospective studies in 
cohorts exposed to high drinking water levels of arsenic often failed to account for disease at 
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lower exposure levels resulting in extrapolation of the dose-response relationship that was 
greatly biased by the high exposure levels.   
USEPA BMD software is not equipped to handle adjustments made for epidemiologically 
significant confounders of age, sex, smoking and other socio-demographic factors. The Strong 
Heart study provided different models of the dose response relationship by eliminating the 
influence of many the confounders that could influence CHD in the unique Native American 
cohort.  The final model eliminated effects of age, sex, smoking, diabetes, obesity and renal 
function.  In addition to using this population based model, the RfD was derived based on the 
BMD analysis of primary mouse data for atherosclerosis, a model system where the intake of 
arsenic was well-controlled and the only confounding variable was the genetic predisposition of 
the mice to atherosclerosis. Although atherosclerosis is not the final clinical manifestation of 
arsenic-induced disease, it is the primary pathogenic process that evidently leads to CHD.  It was 
remarkable that deriving the BMD and RfD from the two different data sets yielded values that 
were similar and within one or two fold of each other.  This suggests that the cardiovascular 
impacts of arsenic are nearly identical between the species as opposed to the observation that 
mice are a poor model for arsenic-induced cancers. 
The burden of CHD due to arsenic was estimated using BMD values from epidemiological data.  
The Rfd was not used for the determination, since it is the dose at which there is no risk of 
disease made more conservative by dividing by the uncertainty of the estimate to account for 
susceptibility in the population.  The BMD reflects the true point of departure where disease 
occurs and thus a dose that would produce a burden of disease.  It is important to emphasize that 
the BMD modeling produced an estimated point of departure that is almost identical to that 
 132 
observed for the exposure of arsenic that posed a significant CHD hazard ratio in the dose 
response analysis in the Strong Heart Study (Moon et al., 2013).  This burden of disease 
estimation quantifies the additional cases of CHD annually over the background incidence rate. 
The estimation however gets restricted by lack of incidence data for CHD in countries and WHO 
regions. Usual disease rates are reported as mortality which is not useful for the current 
estimation. Mortality data do not provide for estimation of morbidity and DALY. Therefore the 
current estimation relies on data from representative countries in two GEMS country clusters M 
and G.  The current BMD estimates provide a conservative estimate, as these are based on 
maximum possible levels of inorganic arsenic in food that is completely bioavailable to cause 
disease. 
6.4 PUBLIC HEALTH SIGNIFICANCE 
This study answers an important public health question regarding global burden of cancer and 
non-cancer disease due to inorganic arsenic in food. Estimating the global cancer and non-cancer 
burden caused by foodborne arsenic exposure will support policies that reduce exposure to 
disease promoting environmental hazards.  Arsenic induced cancers and cardiovascular disease 
have a considerable detrimental effect on global health. The additional annual cases attributable 
to foodborne arsenic exposure are a significant impact on the status of global health.  
An accurate estimation of the extent of foodborne illness is expected to help ensure public health 
security as well as enable socioeconomic development worldwide (Kuchenmuller et al., 2009). 
Estimation of disease burdens like those presented in this thesis, allow evaluation of the current 
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food safety measures and development of new food safety standards. Policy makers can 
prioritize the allocation of limited resources to improve public health in the most efficient and 
effective manner. The knowledge of the burden of disease attributable to food toxicants helps to 
quantify the disease burden in monetary costs. The results demonstrate that a cost-effective 
strategy for reducing disease burden from arsenic in food is to reduce the consumption of 
cultivars that accumulate arsenic in the food. Simple shift in types of foods or amounts of 
contaminated food consumed, as well as providing alternative cultivars with low arsenic content, 
would be cost effective means of reducing disease burden. 
6.5 SUMMARY AND FUTURE DIRECTIONS 
Exposure to arsenic through food is a recent concern, although it has occurred as long as man has 
consumed crops. The scientific community is in the process of determining if exposure to arsenic 
via food raises the same health issues as exposure to arsenic through drinking water. Even if 
human biomarkers for arsenic exposure are available in urine, blood, hair and nails (JECFA, 
2011), it is not possible to determine from these biomarker measurements what portion of arsenic 
exposure comes from drinking water and what portion comes from food.  For the purposes of 
estimating human health consequences associated with arsenic, knowing the overall population 
arsenic exposure matters more than knowing the relative contribution from water vs. food; but 
for the purpose of recommending interventions, it can be helpful to understand the separate 
contributions. There are uncertainties surrounding the proportions of organic vs. inorganic 
arsenic for different food commodities. The inorganic arsenic is of greater toxicological 
importance. Bioavailability of arsenic in different foods tends to vary with the food group or the 
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method of processing of the food. Bioavailability is also influenced by the complexity of other 
food constituents. There is a need for more assessment of the disease risk from the lower end of 
arsenic exposures. Exposure estimates are weakened by difficulty obtaining accurate foodborne 
arsenic exposure data worldwide.   
More research is needed to acquire an understanding of whether inorganic arsenic in food has the 
same toxicological effects, at the same doses, as inorganic arsenic in drinking water. 
Knowledge of the interactions of arsenic with other dietary and environmental risk factors in 
inducing adverse health effects will help to provide more accurate estimates of global disease 
burden due to foodborne arsenic.   
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APPENDIX A. TSENG (1977): TABLE 1. AGE-SPECIFIC AND SEX-SPECIFIC 
PREVALENCE RATE FOR SKIN CANCER (ADAPTED) 
Table A-1 - Tseng (1977): Table 1. Age-specific and Sex-specific Prevalence Rate for Skin 
Cancer (Adapted) 
 
 
Age Males Females 
Per 1000 Number Per 1000 Number 
0-19 - 0 - 0 
20-29 1.0 2 1.1 3 
30-39 9.7 20 1.5 4 
40-49 25.9 40 8 16 
50-59 80.8 99 28.9 38 
60-69 124.8 92 57.0 40 
70+ 209.6 57 53.8 17 
Total 16.1 310 5.6 118 
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APPENDIX B. MORALES ET AL. (2000): TABLE 2. COMPARISON POPULATION 
DATA 
Table B-1 - Morales et al. (2000): Table 2. Comparison Population Data  
 
 
Sex, age 
 
(years) 
All- Taiwan 
 
Southwestern Taiwan 
PYR 
Deaths (n) 
PYR 
Deaths (n) 
Bladder 
cancer 
Lung 
cancer 
Bladder 
cancer 
Lung 
cancer 
Male       
20-25 13,271,386 3 45 2,956,638 2 14 
25-30 11,054,191 4 86 2,175,046 3 26 
30-35 8,628,516 8 144 1,580,019 2 33 
35-40 6,793,545 20 217 1,320,637 6 38 
40-45 6,375,466 50 447 1,327,866 18 89 
45-50 6,384,052 91 951 1,334,769 34 181 
50-55 6,062,515 164 1,852 1,214,443 52 323 
55-60 5,018,542 213 2,882 977,820 61 478 
60-65 3,666,535 345 3,557 739,460 103 595 
65-70 2,443,367 413 3,569 520,965 126 607 
70-75 1,480,126 418 2,658 320,158 130 465 
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75-80 720,375 305 1,318 158,750 88 230 
80-85 287,294 146 512 63,236 32 80 
85+ 105,411 66 152 22,651 15 22 
Female       
20-25 12,612,276 0 39 2,595,529 0 7 
25-30 10,548,089 2 70 1,846,189 2 19 
30-35 8,210,507 2 102 1,402,764 0 17 
35-40 6,458,620 5 205 1,215,899 2 41 
40-45 5,802,856 20 365 1,191,615 8 75 
45-50 5,157,821 41 525 1,111,810 14 112 
50-55 4,335,755 76 730 957,985 36 160 
55-60 3,517,193 124 1,018 774,836 52 200 
60-65 2,776,622 153 1,224 634,758 77 258 
65-70 2,106,715 173 1,280 492,203 68 230 
70-75 1,490,659 185 1,062 342,767 70 190 
75-80 888,468 157 707 199,630 43 108 
80-85 433,245 81 330 96,293 21 45 
85+ 217,590 41 136 46,089 9 10 
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APPENDIX C. NATIONS IN EACH OF THE 13 WHO GEMS CLUSTERS (WHO 
GEMS, 2006) 
Table C-1a - Nations in each of the WHO GEMS clusters A through D (WHO GEMS, 
2006) 
 
 
Cluster A Cluster B Cluster C Cluster D 
Angola 
Burundi 
Cameroon 
Central African Republic 
Comoros 
Côte d’Ivoire 
Djibouti 
Eritrea 
Ethiopia 
Gabon 
Guinea 
Guinea Bissau 
Liberia Madagascar 
Mauritius 
Rwanda 
Cyprus 
Greece 
Israel 
Italy 
Lebanon 
Portugal 
Spain 
Turkey 
United Arab Emirates 
Algeria 
Egypt 
Iraq 
Jordan 
Kuwait 
Libya Arab Jamahiriya 
Morocco 
Saudi Arabia 
Syrian Arab Republic 
Tunisia 
Albania 
Armenia 
Azerbaijan Belarus 
Bosnia and Herzegovina 
Bulgaria 
Georgia 
Iran, Islamic Rep. of 
Kazakhstan 
Kyrgyzstan 
Moldova, Republic of 
Montenegro 
Romania 
Russian Federation 
Serbia Tajikistan 
The former Yugoslav 
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Sao Tome & Principe 
Seychelles 
Sierra Leone 
Somalia 
Uganda 
Yemen 
Republic of 
Macedonia 
Turkmenistan 
Ukraine Uzbekistan 
 
 
 
Table C-1b - Nations in each of the WHO GEMS clusters E through H (WHO GEMS, 
2006) 
 
 
Cluster E Cluster F Cluster G Cluster H 
Austria 
Belgium 
Croatia 
Czech Republic Denmark 
France 
Germany 
Hungary 
Ireland 
Luxembourg 
Malta 
Netherlands 
Poland 
Estonia 
Finland 
Iceland 
Latvia 
Lithuania 
Norway 
Sweden 
Afghanistan 
Bangladesh 
 Cambodia 
 China 
 India 
 Indonesia 
 Lao People’s 
Democratic Republic 
 Malaysia 
 Mongolia 
 Myanmar 
 Nepal 
 Bolivia 
 El Salvador 
 Guatemala 
 Haiti 
 Honduras 
 Mexico 
 Nicaragua 
 Panama 
 Paraguay 
 Peru 
 Saint Kitts & Nevis 
 Saint Vincent & the 
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Slovakia 
Slovenia 
Switzerland 
United Kingdom of Great 
Britain 
and Northern Ireland 
 Pakistan 
 Sri Lanka 
 Thailand 
 Vietnam 
Grenadines 
 
 
 
Table C-1c - Nations in each of the WHO GEMS clusters A to DI through M (WHO 
GEMS, 2006) 
 
 
Cluster I Cluster J Cluster K Cluster L Cluster M 
Benin 
Botswana 
 Cape Verde 
 Ghana 
 Kenya 
 Lesotho 
 Malawi 
 Mozambique 
 Namibia 
 South Africa 
 Swaziland 
 Togo 
 Burkina Faso 
Chad 
Congo, Democratic 
Republic of 
 Congo 
 Gambia 
 Mali 
 Mauritania 
 Niger 
 Nigeria 
 Senegal 
 Sudan 
 Antigua & Barbuda 
 Bahamas 
 Barbados 
 Belize 
 Bermuda 
 Brazil 
 Colombia 
 Costa Rica 
 Cuba 
 Dominica 
 Dominican 
Republic 
Brunei Darussalam 
Fiji 
 French Polynesia 
 Japan 
 Kiribati 
 Korea (Democratic 
People's Republic of) 
 Korea (Republic of) 
 Maldives 
 New Caledonia 
 Papua New Guinea 
 Philippines 
 Argentina 
 Australia 
 Canada 
 Chile 
 New 
Zealand 
 United 
States of 
America 
 Uruguay 
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 United Republic of 
Tanzania 
 Zambia 
 Zimbabwe 
 Ecuador 
 Grenada 
 Guyana 
 Jamaica 
 Netherlands 
Antilles 
 Saint Lucia 
 Suriname 
 Trinidad and 
Tobago 
 Venezuela 
(Bolivarian 
Republic of) 
 Solomon Islands 
 Vanuatu 
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APPENDIX D. USEPA BMD SOFTWARE OUTPUT FOR EPIDEMIOLOGICAL DATA 
(MOON ET AL., 2013) FOR LOGLOGISTIC MODEL (BEST-FIT) 
 
 
 
 
 ====================================================================  
      Logistic Model. (Version: 2.14; Date: 2/28/2013)  
     Input Data File: C:/Shilpi/BMDS240/Data/lnl_Dax_Setting.(d)   
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     Gnuplot Plotting File:  C:/Shilpi/BMDS240/Data/lnl_Dax_Setting.plt 
        Thu Jan 30 22:48:04 2014 
 ====================================================================  
 
 BMDS_Model_Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the probability function is:  
 
   P[response] = background+(1-background)/[1+EXP(-intercept-slope*Log(dose))] 
 
 
   Dependent variable = Effect 
   Independent variable = Dose 
   Slope parameter is restricted as slope >= 1 
 
   Total number of observations = 4 
   Total number of records with missing values = 0 
   Maximum number of iterations = 500 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
 
 
   User has chosen the log transformed model 
 
 
                  Default Initial Parameter Values   
                     background =            0 
                      intercept =     -3.54742 
                          slope =            1 
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           Asymptotic Correlation Matrix of Parameter Estimates 
 
           ( *** The model parameter(s)  -slope    
                 have been estimated at a boundary point, or have been 
specified by the user, 
                 and do not appear in the correlation matrix ) 
 
             background    intercept 
 
background            1        -0.46 
 
 intercept        -0.46            1 
 
 
 
                                 Parameter Estimates 
 
                                                         95.0% Wald Confidence 
Interval 
       Variable         Estimate        Std. Err.     Lower Conf. Limit   Upper 
Conf. Limit 
     background         0.225662            *                *                  
* 
      intercept         -58.2858            *                *                  
* 
          slope               18            *                *                  
* 
 
* - Indicates that this value is not calculated. 
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                        Analysis of Deviance Table 
 
       Model      Log(likelihood)  # Param's  Deviance  Test d.f.   P-value 
     Full model        -1952.54         4 
   Fitted model        -1952.66         2      0.247206      2          0.8837 
  Reduced model        -1956.17         1       7.26439      3         0.06393 
 
           AIC:         3909.32 
 
 
                                  Goodness  of  Fit  
                                                                 Scaled 
     Dose     Est._Prob.    Expected    Observed     Size       Residual 
  ------------------------------------------------------------------------ 
    4.2000     0.2257       202.193   202.000         896       -0.015 
    7.5000     0.2257       201.516   206.000         893        0.359 
   12.4000     0.2257       201.292   197.000         892       -0.344 
   21.8000     0.2696       241.000   241.000         894        0.000 
 
 Chi^2 = 0.25      d.f. = 2        P-value = 0.8837 
 
 
   Benchmark Dose Computation 
 
Specified effect =           0.01 
 
Risk Type        =      Extra risk  
 
Confidence level =           0.95 
 
             BMD =        19.7433 
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            BMDL =        2.24123 
 
 
 
 
 
 
 
 
USEPA BMD software output for mouse data for Exponential models (Best-fit) 
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==================================================================== 
      Exponential Model. (Version: 1.9;  Date: 01/29/2013)  
     Input Data File: C:/BMDS/BMDS240/Data/exp_Dax_Setting.(d)   
     Gnuplot Plotting File:   
        Thu Apr 10 15:14:54 2014 
 ====================================================================  
 
 BMDS Model Run  
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
  
   The form of the response function by Model:  
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      Model 2:     Y[dose] = a * exp{sign * b * dose} 
      Model 3:     Y[dose] = a * exp{sign * (b * dose)^d} 
      Model 4:     Y[dose] = a * [c-(c-1) * exp{-b * dose}] 
      Model 5:     Y[dose] = a * [c-(c-1) * exp{-(b * dose)^d}] 
 
    Note: Y[dose] is the median response for exposure = dose; 
          sign = +1 for increasing trend in data; 
          sign = -1 for decreasing trend. 
 
      Model 2 is nested within Models 3 and 4. 
      Model 3 is nested within Model 5. 
      Model 4 is nested within Model 5. 
 
 
   Dependent variable = Mean 
   Independent variable = Dose 
   Data are assumed to be distributed: normally 
   Variance Model: exp(lnalpha +rho *ln(Y[dose])) 
   rho is set to 0. 
   A constant variance model is fit. 
 
   Total number of dose groups = 5 
   Total number of records with missing values = 0 
   Maximum number of iterations = 500 
   Relative Function Convergence has been set to: 1e-008 
   Parameter Convergence has been set to: 1e-008 
 
   MLE solution provided: Exact 
 
 
                                 Initial Parameter Values 
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     Variable          Model 2           Model 3           Model 4           Model 5 
     --------          -------           -------           -------           ------- 
     lnalpha           1.89729           1.89729             1.89729           1.89729 
         rho(S)              0                 0                   0                 0 
           a           1.18617           1.18617            0.439375          0.439375 
           b         0.0143973         0.0143973            0.001086          0.001086 
           c                --                --                 177.07            
177.07 
           d                --                 1                  --                 1 
 
     (S) = Specified 
 
 
 
                               Parameter Estimates by Model 
 
     Variable          Model 2           Model 3           Model 4           Model 5 
     --------          -------           -------           -------           ------- 
     lnalpha        2.13807           2.13807             1.94856           1.94856 
         rho                 0                 0                   0                 0 
           a           2.58405           2.58405             1.06638           1.06642 
           b        0.00907074        0.00907074        2.70896e-006      2.37356e-006 
           c             --                --                25055.7           28594.1 
           d             --                 1                  --                 1 
 
 
            Table of Stats From Input Data 
 
     Dose      N         Obs Mean     Obs Std Dev 
     -----    ---       ----------   ------------- 
         0      8       0.4625       0.9054 
        10      5         3.05         1.21 
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        50      5         4.42         2.69 
       100      6         8.25        1.475 
       200      8        15.56         4.81 
 
 
                      Estimated Values of Interest 
 
      Model      Dose      Est Mean      Est Std     Scaled Residual 
     -------    ------    ----------    ---------    ---------------- 
          2         0         2.584        2.913            -2.06 
                   10         2.829        2.913           0.1694 
                   50         4.067        2.913            0.271 
                  100         6.401        2.913            1.555 
                  200         15.86        2.913          -0.2868 
          3         0         2.584        2.913            -2.06 
                   10         2.829        2.913           0.1694 
                   50         4.067        2.913            0.271 
                  100         6.401        2.913            1.555 
                  200         15.86        2.913          -0.2868 
          4         0         1.066        2.649          -0.6447 
                   10          1.79        2.649            1.063 
                   50         4.685        2.649          -0.2237 
                  100         8.303        2.649         -0.04917 
                  200         15.54        2.649          0.02348 
          5         0         1.066        2.649          -0.6448 
                   10          1.79        2.649            1.063 
                   50         4.685        2.649          -0.2236 
                  100         8.303        2.649         -0.04909 
                  200         15.54        2.649          0.02343 
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   Other models for which likelihoods are calculated: 
 
     Model A1:        Yij = Mu(i) + e(ij) 
               Var{e(ij)} = Sigma^2 
 
     Model A2:        Yij = Mu(i) + e(ij) 
               Var{e(ij)} = Sigma(i)^2 
 
     Model A3:        Yij = Mu(i) + e(ij) 
               Var{e(ij)} = exp(lalpha + log(mean(i)) * rho) 
 
     Model  R:        Yij = Mu + e(i) 
               Var{e(ij)} = Sigma^2 
 
 
                                Likelihoods of Interest 
 
                     Model      Log(likelihood)      DF         AIC 
                    -------    -----------------    ----   ------------ 
                        A1       -46.35666            6      104.7133 
                        A2       -33.27237           10      86.54474 
                        A3       -46.35666            6      104.7133 
                         R       -74.76534            2      153.5307 
                         2       -50.20914            3      106.4183 
                         3       -50.20914            3      106.4183 
                         4       -47.17703            4      102.3541 
                         5       -47.17703            4      102.3541 
 
 
   Additive constant for all log-likelihoods =     -29.41.  This constant added to the 
   above values gives the log-likelihood including the term that does not 
   depend on the model parameters. 
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                                 Explanation of Tests 
 
   Test 1:  Does response and/or variances differ among Dose levels? (A2 vs. R) 
   Test 2:  Are Variances Homogeneous? (A2 vs. A1) 
   Test 3:  Are variances adequately modeled? (A2 vs. A3) 
   Test 4:  Does Model 2 fit the data? (A3 vs. 2) 
 
   Test 5a: Does Model 3 fit the data? (A3 vs 3) 
   Test 5b: Is Model 3 better than Model 2? (3 vs. 2) 
 
   Test 6a: Does Model 4 fit the data? (A3 vs 4) 
   Test 6b: Is Model 4 better than Model 2? (4 vs. 2) 
 
   Test 7a: Does Model 5 fit the data? (A3 vs 5) 
   Test 7b: Is Model 5 better than Model 3? (5 vs. 3) 
   Test 7c: Is Model 5 better than Model 4? (5 vs. 4) 
 
 
                            Tests of Interest 
 
     Test          -2*log(Likelihood Ratio)       D. F.         p-value 
   --------        ------------------------      ------     -------------- 
     Test 1                         82.99           8            < 0.0001 
     Test 2                         26.17           4            < 0.0001 
     Test 3                         26.17           4            < 0.0001 
     Test 4                         7.705           3             0.05252 
    Test 5a                         7.705           3             0.05252 
    Test 5b                   -9.948e-014           0                 N/A 
    Test 6a                         1.641           2              0.4403 
    Test 6b                         6.064           1             0.01379 
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    Test 7a                         1.641           2              0.4403 
    Test 7b                         6.064           1             0.01379 
    Test 7c                    3.997e-006           0                 N/A 
 
 
     The p-value for Test 1 is less than .05.  There appears to be a 
     difference between response and/or variances among the dose 
     levels, it seems appropriate to model the data. 
 
     The p-value for Test 2 is less than .1.  Consider running 
     a non-homogeneous variance model. 
 
     The p-value for Test 3 is less than .1.  You may want to 
     consider a different variance model. 
 
     The p-value for Test 4 is less than .1.  Model 2 may not adequately 
     describe the data; you may want to consider another model. 
 
     The p-value for Test 5a is less than .1.  Model 3 may not adequately 
     describe the data; you may want to consider another model. 
 
     Degrees of freedom for Test 5b are less than or equal to 0. 
     The Chi-Square test for fit is not valid. 
 
     The p-value for Test 6a is greater than .1.  Model 4 seems 
     to adequately describe the data. 
 
     The p-value for Test 6b is less than .05.  Model 4 appears 
     to fit the data better than Model 2. 
 
     The p-value for Test 7a is greater than .1.  Model 5 seems 
     to adequately describe the data. 
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     The p-value for Test 7b is less than .05.  Model 5 appears 
     to fit the data better than Model 3. 
 
     Degrees of freedom for Test 7c are less than or equal to 0. 
     The Chi-Square test for fit is not valid. 
 
 
   Benchmark Dose Computations: 
 
     Specified Effect = 1.000000 
 
            Risk Type = Estimated standard deviations from control 
 
     Confidence Level = 0.950000 
 
 
                BMD and BMDL by Model 
 
      Model             BMD                BMDL 
     -------        ------------        ---------- 
        2             83.2099            71.4066 
        3             83.2099            71.4066 
        4             36.6051             23.392 
        5             36.6061             23.392 
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APPENDIX E. LIST OF ABBREVIATIONS 
 
AIC  Akaike’s information criterion 
ApoE–/–  Apolipoprotein E-knockout  
ATSDR  Agency for Toxic Substances and Disease Registry 
BFDEA  Blackfoot disease endemic area 
BMD   Benchmark Dose 
BMDL  Benchmark Dose lower bound 
BMR   Benchmark Response 
CAD   Coronary artery disease 
CHD   Coronary heart disease 
CVD   Cardiovascular disease 
DALY  Disability adjusted life years 
EFSA   European Food Safety Authority 
FERG   Foodborne Disease burden Epidemiology Reference Group 
GBD   Global burden of disease 
GEMS  Global Environment Monitoring System 
IARC   International Agency for Research on Cancer 
iAs   Inorganic arsenic 
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IRIS   Integrated risk information system 
JECFA  Joint Expert Committee on Food Additives 
LOAEL  Lowest observed adverse effect level 
MI   Myocardial infarction 
MLE   Maximum likelihood estimates 
MOA   Mode of action 
NOAEL  No observed adverse effect level  
NMSC  Non-melanoma skin cancer 
NRC   National Research Council 
OR   Odds ratio 
POD   Point of departure 
PTWI   Provisional tolerable weekly intake  
PVD   Peripheral vascular disease 
PYR   Person years at risk 
RfD   Reference dose 
RR   Risk ratio 
SAM   S - Adenosyl Methionine 
SD   Standard deviation 
SE   Standard Errors 
SMR   Standardized mortality rate 
UF   Uncertainty factor 
USEPA  United States Environmental Protection Agency 
WHO   World Health Organization 
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